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Abstract
Deciphering the role of Gfi1b gene target Rgs18 in erythro-megakaryocytic lineage divergence.
By
Ananya Sengupta
Adviser: Dr. Shireen Saleque
The molecular programs that govern the specification of erythroid and megakaryocytic lineages
remain incompletely defined. Gene targeting experiments have shown the transcriptional repressor
Gfi (Growth factor independence) 1b to be essential for the generation of both erythroid and
megakaryocyte cells. Transcriptional repression of Gfi1b target genes is mediated mainly by the
cofactors LSD (lysine demethylase) 1 and CoREST/Rcor1 (REST corepressor 1) or other Rcor
factors. To understand the mechanism of Gfi1b action, its target genes were identified by
chromatin immunoprecipitation (ChIP on Chip) screens. In this study we present the role of Rgs18
(Regulator of G protein signaling 18), a GTPase activating protein (GAP) and a transcriptional
target of Gfi1b, in mediating erythro-megakaryocytic lineage specification in murine and human
contexts.
Following identification of Rgs18 as a potential Gfi1b and LSD1 target, its regulation by these
factors was ascertained in erythro-megakaryocytic cells. Subsequently, the role of Rgs18 in
iv

erythro-megakaryocyte differentiation was interrogated by cDNA and shRNA mediated
manipulation of expression in primary hematopoietic progenitors and cell lines. To determine the
role of Rgs18 in vivo rgs18-/- mice have been generated and their phenotypes will be analyzed
shortly. In parallel, to trace the underlying mechanistic alterations responsible for the phenotypes
obtained by the above manipulations, the status of two branches of the MAPK (mitogen activated
protein kinase) pathway and gene expression patterns of the mutually antagonistic transcription
factors Fli1 (Friend leukemia integration [site] 1/ Klf1 (Kruppel like factor 1) were determined in
Rgs18 manipulated cells. Also Rgs18 interacting proteins were identified in megakaryocytic cells.
Rgs18 expression was found to be low in immature megakaryoblasts in keeping with strong Gfi1b
and LSD1 expression, but was reciprocally upregulated in mature megakaryocytes following
declining Gfi1b and LSD1 levels in cells and on the rgs18 promoter. In contrast, expression of
Gfi1b was strong in immature erythroid cells and increased further in mature cells. Manipulation
of Rgs18 expression in murine hematopoietic progenitors and a multi-potential human
hematopoietic cell line produced opposite outcomes in the two lineages, with expression
augmenting megakaryocytic, and potently suppressing erythroid differentiation and vice versa.
These phenotypes resulted from differential impact of Rgs18 expression on the p38 and ERK
branches of MAPK signaling in the erythroid and megakaryocytic lineages. Repercussions of these
signaling changes impacted relative expression of the mutually antagonistic transcription factors
Fli1 and Klf1 and were compensated by ectopic Fli1 expression demonstrating activity of this
transcription factor downstream of Rgs18.
These results identify Rgs18 as a critical downstream effector of Gfi1b and an upstream regulator
of MAPK signaling and Klf1/Fli1 gene expression. Sustained Gfi1b expression during erythroid
differentiation represses Rgs18 and limits megakaryocytic gene expression in these cells. However
v

during the progress of megakaryocytic differentiation, declining Gfi1b levels result in robust
expression of Rgs18 and lineage progression. Preliminary analysis of Rgs18 interactors in
megakaryocytes indicates that Rgs18 likely modulates the MAPK pathway by impacting Gαi,
cAMP, Ras signaling and certain cytoskeletal proteins. These results will be further extended and
confirmed by phenotypic analysis of rgs18-/- mice, and by characterization of novel Rgs18
interacting proteins.
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Chapter 1: Introduction
1.1.Hematopoiesis.
Hematopoiesis is a process by which mature blood cells capable of performing specific and
specialized functions are produced from multipotent stem and progenitor cells as a result of
coordinated cell specific gene expression [1-3]. Hematopoiesis starts during embryogenesis in the
“blood islands” (clusters of erythroblasts surrounded by endothelial cells) of the extra-embryonic
yolk sac shortly after the onset of gastrulation. The first wave of hematopoiesis known as primitive
hematopoiesis occurs at embryonic day (E) 7- 8.5 in mice. The primitive wave of hematopoiesis
was initially defined as being uni-lineage comprising of primitive erythroid cells originating from
hemangioblast precursors (multipotent precursor cells that can differentiate into both
hematopoietic or endothelial cells) and distinguished from subsequent fetal and adult erythroid
cells by their large size and embryonic globin gene expression [4]. These primitive erythroid cells
function as oxygen delivery vehicles for the rapidly growing embryo. These cells also play a
crucial role in vascular remodeling during development and hence are considered critical for the
transition of an embryo to a fetus in the developing mammal [4]. Recent reports of the presence of
megakaryocyte progenitors in the yolk sac around E7.5 along with the primitive erythroid cells
indicates that the first wave of hematopoiesis is bilineage in nature [5-7]. As primitive
hematopoiesis is not sufficient for embryonic survival, the second wave of hematopoiesis starts
around E10.5 - 12.5 in the aorta gonad mesonephros (AGM) region of the embryo with the
emergence of hematopoietic stem cells (HSCs) [3, 5]. The transition from yolk sac to HSC derived
hematopoiesis establishes long term hematopoiesis where HSCs with their self-renewal capacity

and their potential to give rise to lineage specific progenitors then migrate to and populate the fetal
liver around E11 [8] [6].
The murine fetal liver functions as the major hematopoietic organ for the remainder of fetal
development with its hematopoietic function reaching a peak on E13-14 and ceasing during
postnatal day 2-4 [9]. The function of the fetal liver as a major hematopoietic organ is dependent
on its specific microenvironment. This microenvironment is created by various epithelial and
mesenchymal cell types which produce cytokines, chemo-attractants and extracellular matrix
components that interact directly with hematopoietic cells to maintain the hematopoietic potential
of the developing fetal liver [9]. After birth expanding HSCs in the fetal liver eventually move to
the bone marrow establishing the last key event of hematopoietic migration [2, 10] (Figure 1).
Long Term-HSCs possess self-renewal capability while short Term-HSCs produce multi-lineage
progenitor cells which retain limited proliferative potential and a greater capacity to differentiate
into various hematopoietic lineages (Figure 2).
1.2.Emergence and differentiation of Megakaryocyte Erythroid Progenitors (MEPs).
Bipotential megakaryocyte-erythroid progenitors (primitive MEPs) emerge during early
gastrulation around E7.5-8 along with unipotential primitive erythroid and megakaryocyte
progenitors (Meg-Colony Forming Cells [CFCs]) from the hemangioblast precursors present
within the yolk sac of the murine embryo [5]. Around E10.5-11 during the initial stage of
development of the fetal liver as the primary hematopoietic organ, these megakaryocyte
progenitors and primitive MEPs migrate and seed the nascent the fetal liver where definitive
hematopoiesis begins. However, these primitive cells are soon replaced by definitive MEPs arising
from AGM derived HSCs migrating to the fetal liver [5, 6]. Tracking the fate of single HSCs has
2

shown that Megakaryocyte erythroid (MegE) cells or MEPs in turn originate from common
myeloid progenitors during adult hematopoiesis [11, 12] [13] (Figure 2).
MEPs were initially identified from hematopoietic colonies composed of both erythroid and
megakaryocyte cells in vitro that were obtained from single cells and subsequently from isolation
of these progenitors from adult bone marrow, spleen, fetal liver and yolk sacs of mice [5, 14].
Following commitment of MEPs towards the erythroid lineage, the cell progresses to form a
mature red blood cell (RBC) after proceeding through three major stages: The erythroid progenitor
stages (BFU-E, CFU-E, EryP-CFC), Erythroid precursor stages (pro-erythroblast, basophilic
erythroblast, polychromatic, orthochromatic, reticulocyte), and the mature RBC stage [15, 16].
Similarly once committed to the megakaryocyte lineage, the cell proceeds through progenitor
stages

(BFU-Mk,

CFU-MK)

then

differentiates

into

immature

megakaryocytes

(promegakaryoblast, megakaryoblast) and to mature megakaryocytes which are large polypoid
cells capable of producing platelets [17].
Apart from arising from a common progenitor (MEP), both erythroid cells and megakaryocytes
initially share common multifactorial transcriptional complexes and their protein partners, but
these associations become significantly different as differentiation proceeds along each lineage
[18]. These transcriptional complexes regulate the lineage commitment and terminal maturation
of the two lineages by coordinating the chromatin organization of lineage specific genes and
priming their expression [19]. Although the origin and differentiation of MEPs into erythroid and
megakaryocytic cells is well known, the mechanisms that lead to their divergence from a common
progenitor are still incompletely defined [19, 20] .

3

Thus the process of adult hematopoiesis (Figure 2) is sustained throughout an organism’s life time
by a critical balance of two processes (stochastic and instructive): 1. A tight control of lineage
specific transcriptional programs (stochastic) in each cell type that produce and maintain stem cells
or allow lineage commitment and 2. By growth factor (instructive) stimulated signaling pathways
which also promote survival, proliferation and/or maturation of progenitors [10, 21] [22, 23].
1.3. Transcription factors in erythro-megakaryocytic development.
To understand the regulation of hematopoiesis by transcription factors in mammals, researchers
have mostly relied on gene deletion (knockout) and retroviral infection/over-expression
experiments [24-27]. Diverse results from various such experiments have demonstrated the
importance of transcription factors as essential regulators of the production, maintenance, lineage
commitment and specification of HSCs, progenitors like MEPs and of their differentiated progeny
[3, 28-30]. During the primitive hematopoiesis the transcription factor SCL/tal1 along with LMO2
specifies the initiation of a hematopoietic program in hemangioblast. Similarly, Runx1 is necessary
for the generation of HSCs during definitive hematopoiesis in the AGM. Apart from the production
of HSCs, transcription factors like Runx1, Scl/tal-1, and GATA2 are also responsible for cell fate
determination and maintenance of HSCs [3, 30].
As hematopoiesis progresses some transcription factors act as key lineage determinants [3, 30]
thus restricting the fate of multipotential cells by promoting one and/or inhibiting alternative
programs [3]. Dual expression of GATA1 and PU.1 differentiates HSCs to Common myeloid
precursors (CMP). The subsequent commitment of CMPs to the MEP fate is regulated by the
predominance of GATA1 over PU.1 expression (Figure 3). Therefore, the MEP versus
(Granulocyte macrophage progenitor [GMP]) fate decision from CMPs is controlled by the crossantagonism between them. Overexpression experiments have shown that these two transcription
4

factors physically interact and inhibits each other’s functions. Ectopic expression of GATA1 can
reprogram myeloid cells into MEPs while that of PU.1 directs CMPs towards the GMP fate [3133].
Similar to the GATA1/PU.1 antagonism, functional antagonism between the transcription factors
Klf1 (Kruppel like factor1) and Fli1 (Friend leukemia integration (site) 1) is known to be
responsible for the divergence of erythroid versus megakaryocytic cell fates from a bipotent MEP
along with an array of other transcription factors (GATA1, FOG1, GATA2, SCL) and micro RNAs
(like miR-150 and miR-451) [34] . Fli1 with its ETS (E-twenty six) repression domain is an
essential pro-megakaryopoietic transcription factor which represses Klf1, a pro-erythropoietic zinc
finger transcription factor in an MEP cell inclined to a megakaryocytic fate [35]. Similarly, Klf1
inhibits Fli1 expression by binding and repressing the fli1 promoter in a MEP cell leaning toward
an erythroid fate. The mutual antagonism between these two transcription factors controls the
differentiation of erythro-megakaryocytic cells from MEPs [3, 34, 35] (Figure 4). A recent study
has further shown that erythroid or megakaryocyte lineage progression from a MEP cell depends
not only on the anti-correlation between Klf1 and Fli1 levels as mentioned earlier but also the
cross-inhibition of the receptors for erythropoietin and thrombopoietin that specify the erythroid
and megakaryocytic lineages respectively, by these factors [23] (Figure 5).
Apart from transcription factors, experimental studies have revealed chromatin modifiers, cell
cycle regulators, and multiple signaling molecules/cascades to be essential during the process of
hematopoietic lineage commitment [10, 13, 36]. Vincenta et al. 2012 in their model of erythromegakaryocyte development have shown the stage specific expression and requirement of
important transcriptional and signaling regulators during erythro-megakaryopoiesis [37] (Figure
6).
5

1.4.Growth factor independence (Gfi) 1b.
Gfi1b

is

a

transcriptional

repressor

reported

to

bind

to

the

DNA

sequence

(TAAATCAC(A/T)GCA) on its gene target via three of its six carboxy-terminal C 2-H2 type zinc
fingers [38, 39]. It belongs to the Gfi1 family of transcription factors which comprises of two small
nuclear proteins: Gfi1 (55-kDa) and Gfi1b (37-kDa). Apart from harboring the six highly
conserved C-terminal zinc fingers, vertebrate Gfi1 family members also possess well conserved
20 amino acid SNAG (Snail/Gfi) repressor domains at their N- termini and non-conserved
intermediate domains between the SNAG domain and the zinc fingers [40-42] (Figure 7).
Gfi1 and Gfi1b auto-regulate and cross-regulate each other’s expression in a context dependent
manner [42]. Both genes are expressed in hematopoietic cells of which Gfi1b is highly expressed
in erythro-megakaryocyte lineages [43] [44] [45]. Gfi1b is expressed in megakaryocyte erythroid
progenitors (MEPs) and throughout erythroid lineage development with highest expression
reported at the erythroblast stage [42] and differential regulation of Gfi1b expression was reported
during megakaryocyte maturation in Gfi1b:GFP knock-in mutant mice with high expression of
Gfi1b in the progenitors and less in mature megakaryocytes [42]. Due to reports of differential
expression pattern of Gfi1b during megakaryopoiesis, the function and expression pattern of Gfi1b
during megakaryocyte differentiation remains to be further elucidated.
Accordingly disruption of the gfi1b gene in mice is embryonic lethal at ~E15 as gfi1b-/- embryos
display a total failure of definitive (adult type) erythro-megakaryopoiesis and death during the
transition from primitive to definitive hematopoiesis. The lethality results from delayed maturation
of primitive erythrocytes and the complete absence of definitive enucleated erythrocytes [40]
(Figure 8). gfi1b-/- embryos also exhibit abnormal and arrested primitive (yolk sac)
hematopoiesis. The presumptive megakaryocytic precursors present in gfi1b-/- embryos proliferate
6

in the presence of thrombopoeitin, but fails to mature further (Figure 9). A recent report with
conditional gfi1b knockout mice has shown lineage restricted requirement of Gfi1b expression in
erythro-megakaryocyte development in adult bone marrow cells. The conditional mouse strain was
generated by flanking exons 2-5 of gfi1b which encode the N terminal portion of the protein (from
the initiator ATG to zinc finger 2) with loxP sites. For conditional disruption, a floxed gfi1b allele
was combined with germline excised gfi1b knockout allele, so that the single excision event results
in bi-allelic absence of intact gfi1b. Excision was mediated by the Mx-Cre transgene which
excised floxed alleles in the bone marrow upon injection of polyinosinic: polycytidylic acid or by
TetO-Cre which is the doxycycline-inducible Cre transgene. By either of these systems,
conditional disruption of gfi1b resulted in hematopoietic abnormalities and lethality within less
than 3 weeks. Disruption of gfi1b lead to the arrest of the erythroid program as early as the
bipotential MEP stage [46]. In case of megakaryocytes, MEPs progress to the megakaryocyte
lineage in conditional gfi1b mutant mice but then are arrested at the pro-megakaryocyte stage
following nuclear polyploidization, but prior to cytoplasmic maturation. Thus precluding the
production of platelets altogether [46].
Conversely, Gfi1b overexpression has been linked with erythro-megakaryocytic and other
malignancies. A three-fold increase in Gfi1b expression has been reported in patients with
erythroleukemia and megakaryocytic leukemia [47]. A novel single nucleotide insertion in gfi1b
gene has been reported in patients with a unique inherited bleeding disorder causing a frame shift
mutation that disrupts the integrity of the fifth zinc finger and eliminates the coding sequence of
the sixth zinc finger domain. Thus the mutated Gfi1b protein is unable to bind DNA and losses its
transcriptional repression capacity. The patients affected by this disorder exhibit red blood cells of
unequal size, large platelets and moderate thrombocytopenia [48]. A recent study of the hereditary
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condition, Gray platelet syndrome has revealed an autosomal dominant nonsense mutation that
introduces a premature stop codon at amino acid 287 of gfi1b in a subset of the patients. This
mutation results in the deletion of forty four carboxy- terminal amino acids corresponding to zinc
finger 5 leading to a truncated Gfi1b protein. Since zinc finger 5 is known to be required for DNA
binding, the inability of the mutant protein to bind to DNA is likely the primary cause of the
inherent bleeding disorder. The overexpression of mutant Gfi1b in the mouse bone marrow
resulted in severe dysplastic megakaryocytes and platelets showing that Gray platelet syndrome is
caused by dominant negative inhibition of non-mutant protein by the mutant Gfi1b [49]. The
disease is characterized by the defective production of alpha granules in platelets leading to their
grey color and larger than normal size and low count. This is due to failure of megakaryocytes to
efficiently channelize endogenous proteins to the granules. The patients with gray platelets thus
suffer from bleeding tendencies with variable severity [49] .
Gfi1b is an epigenetic regulator that modifies chromatin structure on the basis of its biochemical
function as a transcriptional repressor and recruiter of histone modifiers. Gfi1b recruits the
chromatin modifying proteins LSD1 (Lysine specific demethylase1) and CoREST/Rcor1 (REST
corepressor 1), histone methyl transferases such as G9A and histone deacetylase (HDACs) to its
target gene promoters. Together Gfi1b and its cofactors reversibly inhibit target gene expression
including its own promoter by catalyzing serial histone modifications which lead to gradual gene
silencing [50] (Figure 10). Recruitment of HDACs and LSD1 to its target DNA results in
deacetylation of H3-K9 residues and demethylation of histone (H) 3-lysine (K) 4 residues
respectively. Further recruitment of G9A by Gfi1b facilitates methylation of H3-K9 residues [5052].
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1.5. Gfi1b gene targets.
In order to fully understand the mechanism of action of Gfi1b, knowledge of its target genes is
necessary. Previous studies have demonstrated various potential targets (p21, SOCS1&3, CD3γ,
lymphotoxin-A and Gfi1b itself) [39, 53, 54] in hematopoietic cells. However these targets cannot
completely account for its function and mechanism of action in specifying erythro-megakaryocyte
development. Hence, to understand the transcriptional repression mechanism of Gfi1b and its
associated proteins (LSD1 and CoREST), additional gene targets were identified by chromatin
immunoprecipitation screens (CHIP on chip) for all three proteins (Figure 11).
These screens identified 653 common target genes of the Gfi1b/LSD1/CoREST complex in
erythroid cells [50]. Gene ontology analysis of these Gfi1b/LSD1/CoREST transcriptional targets
revealed them to belong to groups with diverse functions indicating that Gfi1b regulates multiple
biological pathways and processes [50]. Subsequent expression profiling was carried out in control
and LSD1 inhibited (knocked down) erythroid cells to determine the regulation of these genes by
the Gfi1b transcriptional complex [50]. LSD1 knockdown cells were chosen instead of Gfi1b
inhibited cells because of auto-regulation of the gfi1b promoter which prevents effective repression
of this factor by small hairpin (sh) or short interfering (si) RNAs. Depletion of LSD1 from cells
leads to the up-regulation of Gfi1b target gene expression including itself.
Among the prominent targets of Gfi1b identified by the ChIP screen were three family members
of the Rgs (Regulators of G protein signaling) family- Rgs2, Rgs14 and Rgs18 (Figure 12). Upregulation of these three Rgs transcripts in gfi1b-/- fetal liver and LSD1 knockdown cells further
confirmed them to be bona fide and likely direct targets of Gfi1b.
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1.6. Regulators of G protein signaling (Rgs).
Rgs proteins are a diverse group of signaling proteins, with a conserved 120 amino acid long
signature RGS domain that binds directly to Gα subunits of G proteins. Hetero-trimeric G proteins
consist of a GDP-bound Gα subunit associated with a Gβγ heterodimer. The Gβγ subunit assist the
coupling of Gα to the G protein coupled receptors (GPCRs) and also prevent the dissociation of
GDP from Gα. GPCRs represent the largest family of receptors that receive extracellular cues from
the environment and relay them into the cell to elicit appropriate intracellular responses. Upon
binding of an activating ligand the GPCR undergoes conformational changes which result in the
release of GDP and subsequent binding of GTP to the Gα subunit (Figure 13). This Gα-GTP
association also results in the dissociation of Gβγ subunit from Gα-GTP and the activation
downstream effectors like adenylate cyclases, phospholipase-C isoforms, Rho GEFs and several
ion channels that in turn activate downstream signaling pathways. These downstream signaling
pathways remain activated until the hydrolysis of GTP by facilitation from the Rgs proteins. After
binding to the Gα subunit via their RGS domains, the Rgs proteins accelerate the hydrolysis of
GTP thus returning G proteins to their Gα-GDP bound state and resulting in termination of
downstream signaling [55-57].
Rgs proteins interact either directly or via intermediate scaffolding proteins like Spinophilin, and
14-3-3 with G-protein-coupled-receptors (GPCRs) resulting in desensitization of the latter by the
above mentioned mechanism. This leads to termination of downstream signaling that in turn
regulate cell growth, differentiation, motility and intercellular trafficking [55, 57, 58]. Recent
studies have also shown the regulation of Rgs proteins by various mechanisms thus providing
evidence of cross-talk between multiple GPCRs and other signaling pathways [58].
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So far 37 mammalian Rgs proteins have been identified that can be categorized into 7 subfamilies
based on their molecular mass, primary sequence homology and presence of additional domains.
All members of the Rgs family accelerate the GTPase activity of Gα subunits with varying degrees
of selectivity for Gαі, Gαq/11 and Gα12/13 proteins. To perform their canonical GAP activity all Rgs
proteins are localized to the plasma membrane along with GPCRs and G proteins [59-61]. Apart
from the 120 amino acid long RGS box, many Rgs proteins possess extensions of various lengths
containing one or more domains with which they mediate G protein independent functions as well
as interactions with non-canonical partners [58]. Thus a single Rgs protein is often regulated by
various mechanisms while several Rgs proteins can be regulated within a cell by a single
mechanism. Hence the role and regulation of one Rgs protein in one cell type may vary from other
cell types. Some Rgs proteins (Rgs19, Rgs14, Rgs10, Rgs2 and Rgs3) are broadly expressed and
found in most tissues while others have limited patterns of expression like Rgs20 which is
specifically expressed in the brain and Rgs5 which is found in vascular smooth muscles [62].
Among the three Rgs members (Figure 12) obtained as Gfi1b targets from CHIP on Chip screen,
Rgs18 was reported to be highly expressed in megakaryocytes and platelets [63-68]. Since Gfi1b
is a major transcriptional regulator responsible for erythro-megakaryopoiesis and Rgs18 was
identified as one of its target in erythroid cells, we decided to investigate the role and mechanism
of action of this protein during erythroid and megakaryocyte lineage differentiation and its
regulation by Gfi1b and its cofactors during the divergence and determination of these two
lineages.
1.7. Regulator of G protein signaling (Rgs) 18.
Rgs18 was independently identified by two groups upon isolation of novel thrombopoietin (TPO)inducible transcripts in primary megakaryocytes [69] and by sequencing unknown transcripts from
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a LT-HSC cDNA library [65], respectively. Rgs18 is a 235 amino acid long protein that belongs
to the R4 subfamily of Rgs proteins and acts as a GAP for Gαi and Gαq subunits [65, 66, 69].
Consistent with high level expression megakaryocytes and platelets, Rgs18 exhibits is also highly
expressed in predominantly hematopoietic tissues such as the fetal liver, bone marrow and spleen
[65, 66, 69]. It is also expressed in stem cells (LT-HSCs and ST-HSCs) and in more differentiated
progenitors such as GMPs, MEPs [65] [66, 69]. Rgs18 depletion was shown to cause
thrombocytopenia in zebrafish while over-expression increased megakaryocyte differentiation of
mouse HSCs [63]. Unlike its stimulatory role in megakaryocytes, Rgs18 appeared to limit
activation of platelets by restricting the duration of G-protein dependent signaling.
The complex of scaffolding proteins Spinophillin (SPL) and the tyrosine phosphatase (SHP-1)
modulates platelet activation by sequestering two members of the Rgs family Rgs18 and Rgs10.
Before injury The SPL/Rgs/ SHP1 complex helps to maintain the quiescence of circulating
platelets while after injury the complex releases the Rgs proteins to limit platelet activation by
inhibiting GPCR signaling. Thus Rgs proteins help to maintain optimal platelet response to
vascular injury by regulating excessive platelet aggregation which can result in arterial occlusion
[64].
1.8. Rgs proteins and mitogen activated protein kinase (MAPKs) signaling.
MAPKs (ERKs, JNKs and p38MAPKs) are a family of kinases connecting cell-surface receptors
to changes in transcription programs. These kinases are expressed and involved in regulation of
cellular functions like proliferation, differentiation, migration and apoptosis. The binding of
MAPK signaling complexes to scaffold proteins determine the location and duration of MAPK
activation, thus regulating their different signaling outcomes [70].
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In hematopoietic cells, ERK1 and ERK2 also known as p44 MAPK and p42MAPK respectively are
activated by a variety of stimuli including growth factors, ligands for GPCRs, cytokines and other
cell stresses. Upon activation, these proteins phosphorylate and regulate the activity of cytoplasmic
and nuclear proteins that further control myeloid, erythroid and megakaryocytic progenitor
proliferation and differentiation. Thus proper activation and duration of the ERK pathway is
required for ultimate regulation of the balance between proliferation, survival and differentiation
of hematopoietic cells [71] (Figure 14).
The p38 MAPK family consists of four splice variants –p38α, p38β, p38γ, and p38ẟ. Of these,
deficiency of p38α is embryonic lethal and p38α deficient mice die around E16.5 due to anemia
as a result of stress induced abnormal erythropoiesis. Thus p38 MAPK has been reported to be
necessary for initiation of erythroid differentiation and has been reported to be activated by the
erythropoietin (EPO) receptor. p38 MAPK favors erythroid differentiation by stimulating heme
biosynthesis, iron uptake [72]. In contrast, in the bipotent erythro-megakaryoblastic cell line
(K562) p38MAPK down-regulation accompanies megakaryocyte maturation [73].
ERK1/2 MAPK signaling inhibits erythroid differentiation as the inhibitors of ERK pathway in
MEL cell line resulted in promotion of erythroid differentiation and increase in hemoglobin protein
as well as β-globin transcript level. In case of megakaryocytes, ERK1/2 activation was reported
may be essential for megakaryocyte differentiation. But Conde et al. 2010 have shown that
inhibition of ERK failed to block expression of megakaryocyte markers in K562 cells when added
24 hours after stimulation with megakaryocyte differentiation inducer PMA (phorbol 12myristate-13-acetate). Thus ERK activity is essential to initiate megakaryocyte differentiation but
once cells enter the differentiation program, signaling through the pathway is not critical [73].
ERK1-2 (p44/42 MAPK) can be activated by ligands for GPCRs. The G protein and cytokine
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signaling converge to activate the MAPK pathway. Since Rgs proteins limits GPCR signaling by
accelerating GTP hydrolysis of G proteins, they also inhibit their downstream signal transduction
processes including MAPK signaling [74].
1.9.Specific Aims.
1) Determining the regulation of Rgs18 by Gfi1b and its cofactors.
Since the Rgs18 promoter was found to be a prominent target of the Gfi1b/LSD1/Rcor1 repressor
complex in erythroid cells we determined its regulation in both erythroid and megakaryocyte
lineages by these factors. Expression profile of Rgs18 was monitored along with that of Gfi1b and
LSD1 in wild type erythroid and megakaryocytic cells as well as in gfi1b-/- mutant fetal liver cells.
These expression patterns were correlated with Gfi1b and LSD1 enrichment on rgs18 promoter
sequences in different stages of erythroid and megakaryocytic differentiation.
2) Establishing the role of Rgs18 in erythropoiesis and megakaryopoiesis.
Since differential expression of Rgs18 was observed in the erythroid and megakaryocytic lineages,
I next interrogated its physiological role in these cells and determined how it affected the
differentiation of erythro-megakaryocytic cells as follows:
a) Examining the role of Rgs18 in murine and human cell lines and progenitors by manipulating
expression.
The effect of Rgs18 on erythro-megakaryopoiesis was established by manipulating its
expression in appropriate cell lines and in primary cells from mice and determining the resulting
phenotypes. Rgs18 was knocked down or over-expressed by shRNAs and cDNAs respectively.
b) in vivo manipulation of Rgs18 to understand its physiological function.
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Accordingly, a CRISPR-Cas9 mediated complete knockout of rgs18 was performed in mice to
determine its physiological functions in vivo.
3) Determining the mechanism of action of Rgs18.
To delineate the underlying mechanistic alterations responsible for the phenotypes ensuing from
Rgs18 manipulation, I undertook the following approaches.
a) Determining downstream effectors and processes regulated by Rgs18.
To understand how Rgs18 alters MAPK signal transduction processes I investigated the
activation (phosphorylation) status of p38 MAPK, ERK-MAPK proteins and expression pattern
of lineage determining genes like EKLF/Klf1 and Fli1 in Rgs18 manipulated erythroid and
megakaryocyte lineages.
b) Identification of proteins associated with Rgs18 in megakaryocytic cells.
To identify novel Rgs18 associated proteins in megakaryocytes, we performed affinity
purification of Rgs18 protein complexes from megakaryocytes using a recombinant epitope
tagged bait followed by analysis of the complex by mass spectrometry.
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Chapter 2: Materials and methods.
2.1. Plasmid construction.
2.1.1. cDNA preparation and PCR amplification.
Pooled full length cDNAs were obtained from total RNA of L8057 cells using Transcriptor High
Fidelity cDNA synthesis kit (Roche # 05081955001). Murine Rgs18 cDNA (Accession No.
NM_022881) and Fli1 cDNA (Accession No. NM_008026) were PCR amplified using the Expand
long template PCR system kit (Roche # 116818340001) and the primers listed below.
Rgs18: atgtcatggttttcttctctcaatt and taaccaaatggcaacatctgactttacat
Rgs18-Biotag- attcccggggccaccatggatatgtcactggttttcttc and attcccgggtaaccaaatggcaacatctgactt
Fli1- atggacggactattaaggaggct and gtatgggtagtagctgcctaagtgtgaagg
2.1.2. Insertion into TOPO vector.
The PCR amplified products were inserted into TOPO sequencing vector (pcr R4 –TOPO Cat # 450030; Thermo fisher Scientific) and the identity of the insert confirmed by sequence verification.
2.1.3. Sub-cloning into expression vectors.
After sequence verification the inserts were excised out of TOPO vector by digestion with specific
restriction endonucleases and ligated with suitably digested pEF4/myc-His vector (Invitrogen),
pCDH-MSCVTM vector (System Biosciences) and pEF1α Biotag vector. Inserted cDNAs were
confirmed by sequence analysis and protein expression ascertained following transient transfection
into 293T cells.
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2.1.4. shRNAs.
Commercially available Rgs18 shRNAs were purchased from the Mission TM collection (Sigma
Aldrich) and their sequences are listed below:
RGS18 shRNA1 (coding): ccggctcctgssgaagcagtgaaatctcgagatttcactgcttcttcaggagtttttg
RGS18shRNA2 (3’UTR): ccggagtaatgtcacatctagtttgctcgagcaaactagatgtgtgacattacttttttg
RGS18shRNA3 (3’UTR): ccggcatcatctatcttccgaaatactcgagtatttcggaagatagatgatgttttttg
The cDNA and shRNAs expressing plasmids were transduced into L8057, MEL and K562 cell
lines to create Rgs18 inhibited or over-expression stable lines.
2.2. Production and maintenance of stable cell lines.
2.2.1. Cell lines.
The murine hematopoietic cell lines MEL (erythroid), L8057 (megakaryoblastic) and K562
(myeloerythroid) were used for the study as indicated. Provided below is a brief description of
each one.
MEL: Murine erythroleukemia (MEL) cells represent murine erythroid progenitor cells transformed
by Friend’s leukemia virus and arrested at the proerythroblast stage of erythroid differentiation. MEL
cells can be induced to differentiate to more mature orthochromatic erythroblast like cells with
compounds like dimethyl sulfoxide (DMSO) and sodium butyrate [75].
L8057: L8057 cells are a murine megakaryoblastic cell line obtained from irradiated mice. These cells
can be induced to differentiate into mature megakaryocytes with phorbol ester (12-O-tetradecanoyl
phorbol-13-acetate) [76].
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K562: The human multipotent hematopoietic cell line (K562 ATCC® CCL243™) [77] was
derived from a chronic myeloid leukemia patient [78]. It has the potential to differentiate into
erythroid, megakaryocyte and other hematopoietic lineages [79, 80]. In this study they were
induced to differentiate into erythroid cells with sodium butyrate and into megakaryocytes with
phorbol ester.
2.2.2. Stable Cell line production.
Stable Rgs18 overexpressing cell lines were generated by nucleofection (Amaxa cell line
nucleofector kit V # VCA-1003) of Rgs18-pEF4 vector into L8057, MEL and K562 cells. Stable
Rgs18 shRNA expressing (knock down) cell lines were generated by transduction with Rgs18
shRNA expressing lentiviruses (also see below).
2.2.3. Cell culture.
MEL, L8057 and K562 cells were cultured in their respective media: MEL (DMEM medium with
10% FBS), L8057 (50% IMDM, 50% DMEM and 10% FBS), K562 (IMDM with 10% FBS).
Rgs18 inhibited or over-expressing stable cell lines were maintained by suitable antibiotic
selections as listed below:
Rgs18-pCDH, Rgs18shRNA inhibited cell lines - 2µg/ml puromycin
Rgs18-pEF4 cell lines - 0.5 mg/ml zeocin
BirA and Rgs18 bio-tag containing cells - 0.4mg/ml G418 (BirA) and 2µg/ml puromycin (Rgs18biotag).
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2.2.4. Differentiation of MEL, L8057 and K562 cells.
To initiate erythroid cell differentiation, immature MEL (~105) cells were induced to differentiate
with 1.5% dimethyl sulfoxide (DMSO) for 4 days. L8057 cells were induced to differentiate with
50nM 12-O-tetradecanoyl phorbol-13-acetate (TPA) for 4-5 days. The multipotent K562 cells
were induced to differentiate into erythroid lineage by treatment with 2mM sodium butyrate and
megakaryocyte lineage with 50nM of TPA for 4-5 days. The uninduced and induced cells were
harvested as needed for protein and RNA collection or histological staining.
2.3. Primary cell collection, manipulation and culture.
2.3.1. Lenti-viral production in HEK293T cells and transduction of murine cells.
50-60% confluent HEK293T cells in 10 cm tissue culture plates were transfected with a mixture
containing 500µl of BioWhittaker TMUltraMEM (reduced serum media # 12-743F Lonza), 72ul of
Trans ITR 293 reagent Mirus (transfection reagent # MIR2705), 12µg of shRNA or cDNA plasmid
DNA, 9 µg of pPAX2 (lentiviral packaging plasmid) and 3 µg of PMD.2G plasmid (lentiviral
envelope plasmid) DNA to produce shRNA or cDNA packaged lentiviruses as a delivery vehicles
for transduction of primary cells or cell lines.
The following day, 293T medium was replaced with the appropriate target cell medium. Viral
supernatants were collected ~48 hours post transfection and either used directly for transduction
or stored at -800C for future use.
~105 (total fetal liver or cell line) cells were infected with lentiviruses by treatment with 3 ml of
the filtered viral supernatant, 20ng/ml IL3 (only for FLCs) and 8µg/ml polybrene in a 6 well plate
and centrifuged for 2hrs at 2000rpm at 220C and then incubated overnight at 370C. After ~ 24 hrs
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the virus and polybrene were washed off the cells and transduced cells were plated in their
corresponding medium supplemented with antibiotics. The shRNAs were maintained with
puromycin (2µg/ml for cell lines and 1µg/ml for FLCs) and the FLCs and cell lines transduced
with cDNA constructs were maintained with the antibiotics respective to their vector backbone
specific antibiotic resistant gene (pCDH: puromycin 2µg/ml for cell lines and 0.75-1µg/ml for
FLCs).
2.3.2. Culture and manipulation of fetal liver cells.
Total or sorted fetal liver cells (~105) from embryonic day 12.5 (e12.5) staged embryos were
harvested following timed mouse matings and either cultured directly or transduced with Rgs18
cDNA, Rgs18 shRNA and /or Fli1 cDNA carrying lentiviruses as detailed above. Cells were
differentiated into erythroid and megakaryocyte lineages using cytokines (10ng/ml IL3 [#403-ML
R&D system], 20ng/ml thrombopoietin [# 488-TO R&D system] and 10ng/ml stem cell factor
[SCF] [#403-ML] for megakaryocytes, 2Units/ml erythropoietin [#287-TC], 25ng/ml SCF for
erythroid differentiation) either in liquid culture or in semi-solid methylcellulose medium (#
M3234; Stem cell TechnologiesTM). The cells were selected for lentivirus retention with 0.51µg/ml of puromycin and harvested after 4-5 days for erythroid and 5-6 days for megakaryocytic
cultures for various assays and/or megakaryocytic colonies were counted in methylcellulose
cultures.
2.4. Histological staining.
For histochemical analysis, 100 µl of cell suspension (~10 5 cells) were cyto-centrifuged at 400
rpm for 4 minutes onto glass slides, air dried and then subjected to various histological staining
procedures as discussed below:
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2.4.1. May-Grunwald Giemsa staining.
The slides were immersed in May-Grunwald stain (Sigma Aldrich #MG1L) (undiluted) for 3
minutes with periodic dipping; then transferred immediately to freshly prepared 1:20 diluted
Giemsa stain ( #620G-75 Giemsa stain EMDTM) for 15 minutes with periodic dipping and rinsed
with water to remove the extra stain [40]. The air dried slides were mounted with Permount (Fisher
Scientific # SP15-100) and coverslipped.
2.4.2 Acetylcholine esterase assay.
This assay was used to detect the production of acetylcholine esterase enzyme which is a marker
of mature mouse megakaryocytes. The acetylthiocholine substrate used in this assay reacts with
the enzyme and colors mature megakaryocyte cells bright brown [81]. The sample containing
slides were incubated with a substrate solution comprised of 2.3mM of acetylthiocholine iodide
(Sigma life science # A5751-G), 0.1M dibasic sodium phosphate (VWR # BDH8022-5200G),
0.1M sodium citrate ( VWR# BDH8017-500), 30mM copper sulphate (VWR# 7758-99-8), 5mM
potassium ferricyanide (EMD # PX-14552) for 3-5 hours. The stain was fixed with 95% ethanol
for 10 minutes and further counter stained with Harris hematoxylin and saturated lithium carbonate
[40]. The slides were washed, air dried mounted and coverslipped.
2.4.3. Benzidine staining.
Benzidine staining was used to detect mature (heme containing) erythroid cells [82]. O-dianisidine
stock solution (4.9 mM of O-diansidine [# Sigma D-Q143] and glacial acetic acid [0.2% final
solution]) was mixed with one tenth volume of 30% H 2O2. 50 µl of the H2O2/dianisidine solution
was added to 500 µl of cell suspension containing ~10 5 cells. The cells were stained for 10 minutes
at room temperature and centrifuged at 5000 rpm for 5 minutes. The 450 µl of supernatant was
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removed and 100 µl of cells were cytocentrifuged onto glass slides. The air dried slides containing
the cells were then counterstained with May-Grunwald solution [40]. The air dried slides were
mounted and coverslipped.
Stained cells were photographed at 100X and 200X magnifications. The number of positively
stained cells relative to the total number of cells in a defined area was determined using the Image
J TM cell imaging and counting software [83].
2.5. Preparation of total RNA and cDNA.
Total RNA was isolated from 106-107 cells, using the EZNA Total RNA kit (#R6834-02).
cDNA for subsequent qPCR analysis was prepared from the isolated total RNA using the qScript TM
cDNA systhesis kit from Quanta Bioscience (#95047-100).
2.6. Quantitative real time PCR.
Quantified expression profiling of different transcripts was performed by qPCR on an ABI 7500
machine (Applied Biosciences) using Absolute Blue QPCR SYBR Green low ROX Mix
(#AB4323 Thermo Fisher Scientific). Expression was normalized to that for HPRT (hypoxanthine
phosphoribosyl transferase) a house keeping gene. The primers used for qRT PCR amplification
are listed below:
muRgs18: caaagaaacaagagtctctcctgaa, taagaaatctggtaaaagcatccac
mu/hu Rgs18: cttggccaaagaaacaagagtctc, cactgaattcagttttaagaaatctgg
muKlf1: tcttaccctccatcagtacactca, atttcagactcacgtgatgggac;
muFli1: ggaattgtgtaaaatgaacaaggag, tctgtatgggaggttgtgttatagg.
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muRgs2: ctcagaagagggtgtacagtttgat, gtggctttttacataagtcctggta
muRgs6: cagtatatggtgtgacagacgagac, gttttcggatgtcatcttttgtagt
muRgs10: atctacatgaccttcctgtccaata, acttcatgagattgaagatctggtc
muRgs14: gaagtattgctgcgtgtatctacc, gtagaccttaatgtcaggcagagag
muRgs16: agatgtactgggatggagagagtc, gtctcgtgatctatgttcacctctt
muHPRT: gttggatatgcccttgacta, ctaattttactggcaacat
muEB3:

actctcatgacagaaagag, aggttaagcagagcttttt

muBeta-globin major: ctatcatgggtaatgccaaa,agcctgaagttctcaggat
muGYPA: gggattatcggaac, aggagtctgctcaa
muPF4:

gcaagcacccctatataag, ataaacatcggaagattgg

muvWF: ctacagcttgcactattcag, agatgtactctcctctctcg
muGPIIb: gtttatttgtttctgcagcc,acagcaatatcattatagcc
muRgs18bio: tttgatagaaggaagacctcagagacc, atacacatacactatcaaaagaagacaa
hu HPRT: aaattccagacaagtttgttgtagg, ctcaacttgaactctcatcttaggc
huGlobin: catttcggcaaagaattcacccc, tatccttgaaagctctgaatcatgg
huCD36: ttgagagaactgttatggggctata, actccatctgcagtattgttgtaag
huGlycophorinA: tttgcatattttcaggcatggtaac, tgttcccttcttagtctcattctct
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huCD10: tctgcaagtaactttaaggagcaat, attatcagcaatgttttctcccagt
huCD41: ggggatctcaacactacagaatatg, cctctggtagtagaatccaaaatt
huCD61: ctgatgccaagactcatatagcatt, aatgattgtcactaccaacatgaca
2.7. Chromatin immunoprecipitation (ChIP).
ChIP experiments were performed with MEL and L8057 cells as previously described [50, 84-86]
with anti-Gfi1b (Santa-cruz; # Sc8559) and anti-LSD1 (Abcam; #ab17721) antibodies. ~10 6 cells were
used per ChIP reaction, crosslinked with 1% formaldehyde, sonicated, precleared and incubated with
5-10µg of antibody. Complexes were washed with high and low salt buffers, and the DNA was
extracted and precipitated.
Primers used for qPCR amplification of ChIP DNA were:
Rgs18 promoter (upstream): tcatttccttcaacaattcagtaca, cgaatctttcctcagatttttctta.
Rgs18 promoter (downstream): atgtgtgaatcaaaagagaaaacttt, cacagatattcatcaatcatgctactt
Sµ: cttgagccaaaatgaagtagactgt, acagtccagtgtaggcagtagagtt
2.8. Flow cytometric analysis.
For flow cytometric analyses of surface markers, 2x105 cells fresh or cultured primary cells were
resuspended in 100 µl of FACS buffer (3% FBS in PBS) along with 1:500 dilution of Fc blocking
reagent anti- mouse CD16/32 (e bioscience #2014-11) and incubated on ice for 5 minutes then
washed and incubated with FITC-conjugated anti-mouse CD9 or CD71 antibodies and APCconjugated anti-mouse CD41 or Ter119 antibodies (eBioscience) [1:200 dilution] at 4 0C for 30
minutes. The cells were then washed, strained and analyzed on a BD LSRII Analyzer (Becton
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Dickinson). For FACs sorting the cells were labeled with lin-FITC and c-kit-PE antibodies and the
lin-ckit+ cells sorted on a BD FACS Aria (Becton Dickinson).
2.9. Preparation and analysis of protein samples.
2.9.1. Whole cell lysate preparation.
~5X105 cells were collected by centrifugation and lysed with whole cell lysis buffer (50mM Tris
HCL, 150 mM NaCl, 1mM EDTA, 10% Triton) or NP40 lysis buffer (0.5% NP-40, 50mM Tris
pH 7.5, 100mM NaCl, 0.1mM EDTA, 10% glycerol) supplemented with protease inhibitors
(#P8340-1M; Sigma Aldrich) by incubating for 30 minutes at 4 0C with agitation. The cell lysates
were centrifuged at 13000 rpm for 10 minutes at 40C and the supernatant (protein) was collected
in a chilled tube. The protein concentration of the cell lysate was determined by Bradford assay
(Bio-Rad reagent, # 5000006) and 30-60 µg of total protein was loaded in 10% or 15% SDS-PAGE
gels for analysis.
2.9.2. Analysis of protein samples.
SDS gels were either stained with Coomassie blue (Invitrogen# LC6060) for visualization of total
protein or transferred onto PVDF membranes and blotted with different antibodies. Antibodies
used were anti-Gfi1b (Santa-cruz; #Sc8559), anti-LSD1 (Abcam; #ab17721), anti-Rgs18 (Abcam;
#ab25917), and anti-P42/44-MAPK (#4695), anti-phosphoP42/44-MAPK (#4370S), anti-P38
(#2371), anti-phosphoP38 (#4511S) from Cell Signaling Technologies.
2.10. Streptavidin-agarose affinity chromatography.
To obtain protein complexes with recombinant biotagged Rgs18, 1-2 liters L8057 (~1X 10 9) cells
were lysed with NP40 lysis buffer (0.5% NP40, 10% glycerol, 50mM Tris pH 7.5, 150mM NaCl,
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0.1 mM EDTA) as described above. The supernatants from the lysed cells were pre-cleared by
mixing with a 1:10 ratio of a 50% prewashed agarose bead slurry and the mixture was incubated
at 40C for 2 hours with agitation. The mixture was centrifuged at 3000rpm for 10 minutes at 4 0C
and the supernatant was added to the 1:10 ratio of a 50% prewashed streptavidin- agarose bead
slurry. The mixture was incubated overnight at 40C with rocking and then centrifuged at 3000rpm
for 10 minutes followed by 3 washes with NP40 wash buffer (0.5% NP40, 50mM Tris pH 7.5,
150mM NaCl, 0.1 mM EDTA). After washing away non-specific material, the proteins bound to
the streptavidin-agarose beads were eluted with of 2XSDS loading buffer (1:1 ratio of beads plus
buffer) by heating at 95-1000C for 5 minutes followed by centrifugation at room temperature at
13000 rpm for 1 minute. Affinity precipitation of Rgs18 was confirmed by Western blotting of
10% of the precipitated material. The remainder of the precipitate was resolved on a 4-15% SDSPAGE gel for tryptic digestion and analysis.
2.10.1. Simply Blue staining.
The SDS-PAGE gel was incubated with ~20 ml of SimplyBlue TM SafeStain (Invitrogen# LC6060)
for 30 minutes and destained by multiple washes with deionized water and then submitted for mass
spectrometric analysis.
2.11. Strategy for Rgs18 gene edited mice production.
2.11.1 Rgs18 guide RNA design strategy.
Rgs18 mutant mice were produced using CRISPR (clustered regularly interspersed short
palindromic repeats) Cas9 (CRISPR associated protein 9) mediated gene editing [87]. This
strategy consists of two components - a guide RNA (gRNA) and a CRISPR associated
endonuclease (Cas9). The gRNA is a short synthetic RNA composed of a “scaffold” sequence
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necessary for Cas9-binding and a user-defined ∼20 nucleotide “targeting” sequence with which
the genomic target is modified. This system can be used to generate knock-out cells or animals by

co-expressing both gRNAs specific to the gene to be targeted along with the Cas9 endonuclease
in appropriate cells. Upon co-expression the Cas9 and gRNAs form a riboprotein complex at the
target loci by annealing of the 3’ end of the guide RNA to the target sequence. This complex
formation also activates Cas9 from an inactive conformation to an active DNA binding state. The
Cas9 endonuclease then cleaves the target DNA to produce a double stranded break which is
subsequently repaired by the cells non-homologous end joining (NHEJ) machinery with the
introduction of errors at a certain frequency [87].
We utilized the transgenic facility at MSKCC (Memorial Sloan Kettering Cancer Center) to
perform gRNAs targeting of the rgs18 locus in the vicinity of the initiator ATG codon (on exon1).
Plasmids expressing hybrid gRNAs composed of a segment complementary to the targeting
sequence and a tracrRNA (trans-activating CRISPR RNA), the cas9 endonuclease and a selectable
marker (puroR) were introduced into zygotes. These injected embryos were then transferred to
foster mothers who then gave birth to rgs18 genome edited mosaic founder mice.
Following is the list of four gRNA sequences used for targeting the first rgs18 exon in the vicinity
of the initiator ATG codon.

#1: caagcatcgaggccaaaatc, #2: ttcaaactaatgcatgggtc, #3:

caaactaatgcatgggtca, #4: aaagaagaaacaagcatc. The rgs18 genomic sequence in the vicinity of
exon1 and the sequences of the gRNAs are shown in Figure 15.
2.11.2 Determination of rgs18 mutations in founder mice.
a) T7 endonuclease 1 assay: This assay was also performed at MSKCC to identify rgs18 gene
targeted founders. The T7 endonuclease1 assay identifies heteroduplex DNA that results from the
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annealing of modified DNA strands produced upon guide RNA-Cas9 mediated editing of DNA
strands with wild type strands. This assay relies on the property of the T7 endonuclease to
recognize and cleave the mis-matched DNA duplexes. In this assay, Rgs18 exon 1 sequence was
amplified from the genomic tail DNA of rgs18 gene edited founder mice with the following
primers- atctgaggaaagattcggga, cactccaatcaatatattttcaac. The PCR samples were loaded on the gel
and the correct bands were cut to extract the DNA. The purified PCR amplified DNA were
denatured, reannealed and then subjected to T7 endonuclease digestion. Amplicons from WTDNA form only homoduplexes and are not digested while gene edited mice generally possess both
the wild type and one or more mutant loci which produce heteroduplexes with kinks resulting from
mismatches that are recognized and cleaved by the endonuclease. The products are then resolved
on a 1.5% agarose gel. The gel image obtained from T7 endonuclease assays on rgs18 gene edited
mice at MSKCC is shown in the result section. The presence of two or more bands being indicative
of T7 endonuclease digestion of indels in the rgs18 locus.
b) Insertion into TOPO cloning vector for sequence verification: Tail genomic DNA obtained from
rgs18 founder mosaic mutant mice were PCR amplified with the primers atctgaggaaagattcggga,
cactccaatcaatatattttcaac and were inserted into the TOPO (pcrR4 –TOPO # 45-0030 Thermo fisher
Scientific) vector for sequencing. The sequences obtained were further compared with the wild
type rgs18 sequence to determine changes in the DNA and especially in the open reading frame
due to generation of the CRISPR induced indels.
2.11.3. Design of alternative PCR strategies to genotype rgs18 mutants.
Based on the above mentioned initial sequence analyses, founders #12, #34 and #38 were selected
for breeding to produce germline transmission.
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Following the determination of the sequences corresponding to the different gene edited lesions in
the rgs18 locus, specific primers were designed as indicated in Figure16 to specifically amplify
the DNA corresponding to a particular lesion versus that for wild type DNA.
The Rgs18 mutant mice were genotyped by PCR using the following primers:
Rgs18 (WT): atggatatgtcactggttttcttc, cctgattttggcctcgatgcttgt
Rgs18 (#12 and #34): atggatatgtcactggttttcttc, aattttacctgattttggcctctg
Rgs18 (#38): atggatatgtcactggttttcttc, tacctgattttggcctcgatttttgct
2.12. Software and computer analysis.
ImageJ: Quantitative analysis of histochemical samples was performed by counting numbers of
positively stained cells relative to the total cell population for a defined image area using the Image
JTM cell imaging and counting software [83].
FlowJo: The data from the flow cytometric experiments were analyzed and represented using
FlowJo V10 software (FlowJo Enterprise).
ANOVA: Data from all qPCR reactions were calculated for standard deviation from three
independent experiments and p values were calculated by “One way analysis of variance”
(ANOVA) or by multiple t test followed by Halm-Sidak post- hoc test as applicable.
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Chapter 3: Results
3.1. Specific Aim1: Determining the regulation of Rgs18 by Gfi1b and its cofactors.
3.1.1. Differential repression of Rgs18 by Gfi1b and LSD1 in erythro-megakaryocytic
lineages.
3.1.1.1 Analysis of rgs18 promoter sequence and identification of putative Gfi1b binding
sites.
The Rgs18 promoter was identified as a prominent target of the Gfi1b/LSD1/Rcor1 transcriptional
complex following chromatin immunoprecipitation (ChIP on chip) screens with antibodies against
all three proteins [50] in erythroid (MEL) cells. Examination of rgs18 promoter sequences
obtained from the mouse promoter arrays of these ChIP-on-chip screens [84, 85] revealed the
presence of quasi-consensus (AAATCT) and consensus (AAATCA) Gfi1/1b binding sites [88] in
the 5’ UTR and proximal protein coding regions of murine rgs18 respectively (Figure 17). This
identified the rgs18 promoter as a putative target of the transcriptional of the Gfi1b transcriptional
complex and indicated possible regulation of Rgs18 by Gfi1b and its cofactors in erythroid cells.
3.1.1.2. Stage specific expression patterns of Rgs18, Gfi1b and LSD1 in erythromegakaryocytic cells.
As discussed above, Gfi1b and its cofactor LSD1 generally repress their gene targets [84, 89].
Therefore we first monitored expression of Rgs18, Gfi1b, LSD1 and β-actin (as a loading control) in
immature and mature erythroid (MEL) and megakaryocytic (L8057) cells to determine the reciprocal
relationship, if any, between them.
The MEL (murine erythroleukemia) cell line is a murine erythroid progenitor line arrested at the
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proerythroblast stage that can be induced to differentiate into relatively mature cells (orthochromatic
erythroblasts) with dimethyl sulfoxide (DMSO) or sodium butyrate [90]. L8057 is a murine
megakaryoblastic cell line that can be induced to differentiate into mature megakaryocytes with
phorbol ester [76].
As shown in Figure 18, Rgs18 was found to be low in uninduced L8057 in keeping with strong Gfi1b
and LSD1 expression in these cells, but was strongly upregulated upon differentiation of these cells to
megakaryocytes following a sharp decline in Gfi1b and LSD1 levels in the induced cells. In contrast,
expression of Gfi1b was strong in uninduced proerythroblast-like MEL cells and increased further in
DMSO induced MEL cells (Figure 18). Conversely, Rgs18 expression which was moderate in
immature erythroid cells, exhibited a further a reciprocal decline during maturation. As reported
previously [89], LSD1 levels remained approximately uniform during maturation of MEL cells. These
experiments confirmed inverse expression patterns of Rgs18 and Gfi1b/LSD1 in erythromegakaryocytic cells.
3.1.1.3 Dose dependent enrichment of Gfi1b and LSD1 on the rgs18 promoter elements.
To confirm association of Gfi1b and LSD1 with the Rgs18 promoter, ChIP-qPCR was performed in
uninduced (immature) and induced (mature) MEL and L8057 cell lines. (These ChIP experiments
were performed by Ghanshyam Upadhyay; Figure 19). In accordance with their expression profiles,
Gfi1b and LSD1 showed substantial enrichment on both putative Gfi1b binding elements in uninduced
L8057 cells but greatly reduced enrichment in induced L8057 cells. In contrast, marginally higher
enrichment of these proteins was observed in mature (induced) versus immature (uninduced) MEL
cells. Surprisingly, the upstream “semi-consensus” Gfi1b binding element consistently showed greater
enrichment for Gfi1b and LSD1 relative to the downstream “consensus” element as defined by
previous reports [17], in both lineages, demonstrating the relatively greater affinity of the upstream
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site for these proteins.
3.1.2. Expression of Rgs18 in LSD1 inhibited and gfi1b deficient erythro-megakaryocytic
cells.
To demonstrate repression of the rgs18 promoter by LSD1, Rgs18 expression was measured in
immature erythroid and megakaryocytic cells upon LSD1 inhibition. Up-regulation of Rgs18
expression was seen in both cell types although to different extents (Figure 20 A-B). These results
demonstrated repression of Rgs18 by LSD1 in the two cell lines.
To confirm repression of rgs18 by Gfi1b in primary cells, their message (mRNA) levels were
monitored in control (wild type and heterozygous) versus gfi1b mutant hematopoietic cells. Since
auto-repression of the gfi1b promoter by itself [84, 91] prevents effective inhibition of this factor by
shRNA mediated mechanisms, we were unable to monitor Rgs18 mRNA levels following inhibition
of Gfi1b.
We determined Gfi1b and Rgs18 expression in total embryonic day 12.5 (e12.5) fetal liver cells from
all three genotypes (gfi1b+/+, gfi1b+/-, gfi1b-/-). Wild type e12.5 fetal livers are predominantly
erythroid in composition with ~80% of cells exhibiting robust ter119 (mature erythroid cell marker)
expression) in addition to having limited numbers of HSCs, MEPs and megakaryocyte progenitors
(Figure 21; courtesy G. Upadhyay). Consistent with the indistinguishable phenotypes of wild type
versus gfi1b+/- fetal livers as reported previously [92], we observed a marginal decrease in Gfi1b, and
a similarly modest (~20%) increase in Rgs18, message levels respectively, in the heterozygous cells
relative to wild type controls (Figure 22). In contrast complete absence of Gfi1b in the homozygotes
produced a substantial elevation of Rgs18 message relative to wild type cells in this primarily erythroid
tissue (Figure 22).
Next, to investigate the expression of Gfi1b and Rgs18 in primary megakaryocytes we cultured wild
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type e12.5 fetal liver cells with megakaryocytic cytokines (TPO, IL3) to preferentially expand this
lineage, which is under represented in the fetal liver relative to erythroid cells [93]. These cytokines
induce megakaryocyte progenitors to differentiate into mature megakaryocytes as well as promote
uncommitted HSCs and MEPs present in the fetal liver populations to choose this fate. Differentiation
of fetal liver progenitors to megakaryocytes was monitored by visual inspection and expression of the
megakaryocytic differentiation marker glycoprotein IIb (GPIIb, also known as CD41) (Figure 23A).
Differentiation of wild type progenitors into megakaryocytes was accompanied by a gradual decline
in Gfi1b, and a concomitant and reciprocal increase in Rgs18, expression (Figure 23A), demonstrating
progressively attenuated repression of the rgs18 promoter upon decreasing Gfi1b expression. In
contrast, although Rgs18 levels were higher in gfi1b-/- fresh (d0) fetal liver cells relative to controls,
it remained unchanged upon differentiation of mutant cells along the megakaryocyte lineage relative
to that observed on day 0 (Figure 23B). This lack of a net increase in Rgs18 mRNA levels in gfi1b-/cells relative to the day 0 control confirms minimal or no repression of Rgs18 by Gfi1b during
megakaryocytic differentiation and therefore no noticeable rise in Rgs18 expression in the absence of
gfi1b unlike the increase observed in wild type cells.
Overall, the results depicted in Specific Aim1 collectively demonstrate dose dependent and differential
repression of Rgs18 by Gfi1b and its cofactor LSD1 in erythroid versus megakaryocytic cells resulting
in their reciprocal expression in the two lineages.
3.2. Specific Aim2: Determining the role of Rgs18 in erythropoiesis and megakaryopoiesis.
3.2.1. Examining the role of Rgs18 in murine and human cell lines and progenitors by
manipulating expression.
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3.2.1.1. Manipulation of Rgs18 expression in murine (MEL and L8057) cell lines, and in
murine fetal liver (hematopoietic) cells.
Given that Rgs18 is expressed both in erythroid and megakaryocytic cells, we next interrogated its
role in their differentiation. Rgs18 expression was manipulated in L8057 (Figure 24A) and MEL cell
lines as well as in fetal liver progenitor cells (Figure 25C) by shRNA mediated inhibition and cDNA
i.e. protein over-expression.
Consistent with previous reports in other systems [67, 94], inhibition of Rgs18 retarded
megakaryocytic differentiation of induced L8057 cells (Figure 24) as well as fetal liver progenitors
cultured in vitro (Figure 25). This effect was demonstrated by a decrease in the expression of
differentiation markers relative to a housekeeping gene (HPRT) (Figure 24B, Figure25A), a reduction
in the number of acetylcholine esterase (a mouse megakaryocyte marker) positive cells (Figure 24D,
Figure25D) and a diminution in the number of cells displaying the mature megakaryocytic cell surface
markers CD9 and CD41 (Figure 25E). The reverse result, namely augmentation of differentiation was
obtained upon over-expression of Rgs18 in this lineage (Figure 24C and D, Figure 25B, D, E). These
results confirmed previous reports documenting the stimulatory role of Rgs18 in megakaryocytic
differentiation [67, 94].
To confirm the validity of the Rgs18 knockdown phenotype and rule out shRNA mediated off-target
effects, we over-expressed the protein coding segment of the Rgs18 cDNA in L8057 cells depleted for
endogenous Rgs18 by shRNAs targeting the 3’UTR (3’ untranslated region) of the native transcript.
Following induction with TPA, cells expressing Rgs18 shRNAs and cDNAs reverted back to the
control state (Figure 24E) confirming the fidelity of the Rgs18 knock down phenotypes.
In sharp contrast to the above phenotype, manipulation (inhibition and over-expression) of Rgs18
produced exactly the opposite outcome in both the murine MEL (erythroid) cell line (Figure 26) and
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in primary erythroid cells (Figure 27). Rgs18 inhibition produced a marked increase in differentiation
(Figure 26B, C and Figure 27A, C), as judged from differentiation marker analysis, benzidine
staining (for heme positivity), and relative expression of surface markers Ter119 (a marker of mature
erythroid cells) versus c-Kit (a common marker of uncommitted progenitors) (Figure 27D).
Conversely, Rgs18 over-expression resulted in decreased differentiation of erythroid cells (Figure 27
B, C, D).
Once again, to confirm the validity of the Rgs18 knockdown phenotypes we performed similar rescue
experiments in erythroid cells as discussed above for megakaryocytes (Figure 26 D). Collectively,
these results demonstrated a positive role for Rgs18 in megakaryocytic differentiation and a hitherto
unknown function of Rgs18 in effectively inhibiting erythroid differentiation.
3.2.1.2. Manipulation of Rgs18 expression in lineage negative (Lin -) c-Kit+ FLCs.
To further substantiate the analogous effects of Rgs18 on hematopoietic progenitors and to understand
whether Rgs18 regulates cell fate choice of MEPs, Lin-c-Kit+ cells representing lineage marker (CD28, NK1.1, Ter119, Gr-1) negative and progenitor (c-kit) marker positive hematopoietic progenitors
comprising HSCs, MEPs as well as other undifferentiated progenitors were sorted out from e12.5 fetal
livers (courtesy G. Upadhyay; Figure 28 A) and transduced with Rgs18 shRNAs or cDNAs.
The transduced progenitors were then co-cultured with a mixture of cytokines (erythropoietin, SCFerythroid, TPO, IL3- megakaryocytic) to promote simultaneously differentiation along both lineages
and then analyzed for relative CD41 versus Ter119 expression. The FACS analysis data showed that
inhibition of Rgs18 increased the percentage of Ter119 (mature erythroid marker) positive cells
(quadrant 3 of histogram) as compared to the control shRNA treated cells. Whereas over-expression
of Rgs18 resulted in increased percentage of mature megakaryocyte marker CD41 (quadrant 2 of
FACS histogram) positive cells and vice versa. These results further confirmed the stimulatory effect
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of Rgs18 expression on megakaryocytic, and suppressive effect on erythroid, differentiation in a
progenitor population subjected to mixed culture conditions (Figure 28 B).
3.2.1.3 Manipulation of Rgs18 expression in the human hematopoietic K562 cell line.
Finally, to delineate the effects of Rgs18 expression in human cells, Rgs18 cDNA was over-expressed
in the human multipotent hematopoietic cell line K562 [77] followed by differentiation along either
lineage [79, 80]. The K562 (erythromyeloblastoid) cell line has the potential to differentiate into
erythroid and megakaryocytic cells following induction with sodium butyrate and TPA, respectively.
Expression of murine Rgs18 cDNA which is ~90% identical to its human counterpart (NP_570138)
also resulted in suppression of erythroid, and stimulation of megakaryocytic, differentiation relative
to a vector control as evidenced by differentiation marker mRNA analysis and histochemical staining,
in these human cells (Figure 29 A-E).
The cumulative results of these multiple approaches described in Specific aim 2.1 unequivocally
demonstrate the dual role of Rgs18 in actively promoting megakaryopoiesis and in restricting
erythropoiesis in both mouse and human contexts. This, in conjunction with the reciprocal expression
of Rgs18 and its repressor Gfi1b as demonstrated in Specific aim 1, suggest that the high level of
expression of Gfi1b in MEPs and erythroid cells promotes this fate by repressing Rgs18 and keeping
megakaryocytic differentiation in check. However, in cells adopting a megakaryocyte fate, declining
Gfi1b levels upregulate Rgs18 expression and drive differentiation of these cells.
3.2.2. In vivo disruption of the rgs18 gene to determine its physiological functions.
3.2.2.1. CRISPR/Cas9 mediated rgs18 knockout mouse design and generation.
Expression of Rgs18 is most robust in hematopoietic cells such as megakaryocytes, platelets [69],
and to a lesser extent in erythroid cells, MEPs, HSCs and lymphocytes [65] and in tissues like fetal
36

liver, bone marrow and spleen [65]. Therefore we decided to delete rgs18 in the germline with the
expectation that the most prominent phenotype would be obtained in these cells. To do so we
utilized, a CRISPR-Cas9 targeting (clustered regularly interspaced short palindromic repeatCRISPR associated nuclease 9) strategy [87]. rgs18 genome edited mosaic founder mice were
generated in the transgenic facility of MSKCC (Memorial Sloan Kettering Cancer Center) by Dr.
Peter Romanienko and the transgenic team lead by Dr. Willy Marks. The procedure followed to
generate these mosaic founder mice is explained in detail in the Methods section of the thesis.
The founder generation was screened for editing of the rgs18 locus by the T7E1 (T7 endonuclease)
assay also at MSKCC to identify the insertion or deletion of sequences (indels) created at target
locus. T7 endonuclease is a mismatch-specific DNA endonuclease that is used for detecting
insertion/deletion mutations generated by genome engineering. This enzyme targets and digests
mismatched hetero-duplex double stranded DNAs obtained by PCR to produce multiple smaller
DNA fragments that can be visualized by agarose gel electrophoresis [95]. Figure 30 shows the
indels (multiple bands) generated by the T7 assay from three such founder mice (#12, #34 and
#38).
Subsequently the sequences corresponding to the indels was determined by PCR amplification,
sub-cloning and sequencing of the DNA in the region of the indels from the founder mice. A
sampling of indel sequences and the corresponding translational frame shifts resulting from them
is presented in Figure 31. The figure shows the sequences of the four founder mice that exhibited
frameshift indels leading to premature stop codons. These rgs18 edited loci encode mutant RNAs
that should produce either severely truncated proteins or none at all if they are rapidly degraded
by nonsense mediated decay.

37

These mosaic founder mice (some with multiple lesions) were then backcrossed with wild type
mice to produce heterozygotes. rgs18 heterozygous mice harboring lesions depicted in Figure 31
were genotyped by PCR amplification with lesion specific primers described in “Materials and
Methods”.
Currently we are breeding the heterozygous Rgs18 mutant population in our own CCNY mouse
facility to expand the colony and back cross them into the C57Bl/6 strain. Future experiments with
the mutant mice are elaborated in the “Discussion” section of the thesis.
3.3. Specific Aim3: Determining the mechanism of action of Rgs18.
3.3.1. Determining downstream effectors and processes regulated by Rgs18.
3.3.1.1. Differential regulation of MAPK signaling by Rgs18 in erythroid and
megakaryocytic cells.
To delineate the underlying mechanistic alterations responsible for the phenotypes ensuing from
Rgs18 manipulation, we interrogated the status of two branches of MAPK (mitogen activated protein
kinase) signaling in these cells. The p38-MAPK and the P44/42-ERK (extra-cellular signal regulated
kinase) pathways are known to be impacted by G protein signaling [96], while also being implicated
in erythro-megakaryocytic differentiation [71]. Specifically, ERK and P38MAPK proteins oppositely
regulate these lineages by promoting proliferation of hematopoietic (megakaryocytic), and
differentiation of erythroid, cells respectively [71]. Since Rgs proteins attenuate G protein activation,
they are known to negatively impact MAPK signaling [96, 97]. Accordingly, Rgs18 levels and activity
were expected to correlate inversely with MAPK signaling.
This was indeed found to be the case for ERK signaling in megakaryocytes (L8057 cells) where Rgs18
inhibition resulted in enhanced, and over-expression in diminished, phospho-ERK (pERK) levels
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(Figure 32A and B) indicating an inverse correlation between Rgs18 expression and the activity of
this MAPK pathway. Likewise, p38MAPK phosphorylation was also sharply attenuated upon Rgs18
over-expression and enhanced upon inhibition (Figure 32D and E). These observations indicated that
both p38 and ERK pathways are negatively impacted by Rgs18 activity in megakaryocytes. These
results were confirmed by time course induction experiments that clearly demonstrated attenuated
decay of ERK and p38 phosphorylation during differentiation in Rgs18 inhibited cells relative to
controls (Figure 33).
Although the effect of ERK signaling on proliferation versus differentiation of megakaryoblasts is
controversial with different reports supporting its stimulation of one or the other process [71, 98], our
observation of heightened differentiation of L8057 cells following downregulation of this pathway (by
Rgs18) clearly demonstrates an inverse relationship between ERK signaling and the differentiation of
these cells. On the other hand reduced p38 signaling upon Rgs18 over-expression, likely contributes
further to the attenuation of erythroid characteristics and gene expression, in these cells (Figure 32
G).
In contrast Rgs18 depletion in erythroid (MEL) cells, diminished pERK levels (Figure 32 C) while
augmenting both P38 protein and phosphorylation levels (Figure 32 F) to co-operatively increase
differentiation. Thus, the phospho-p38 (p-p38) response was similar in both lineages and correlated
inversely with Rgs18 activity, while the pERK response was diametrically opposite in erythroid and
megakaryocytic cells. Overall, the alterations in MAPK signaling upon Rgs18 manipulation illustrate
the likely molecular mechanisms responsible for the corresponding phenotypic alterations in
differentiation, in each lineage (Figure 32 G).
3.3.1.2. Rgs18 determines the equilibrium between Klf1 and Fli1.
To investigate gene expression changes downstream of Rgs18 and to connect MAPK signaling with
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expression of Eklf/Klf1 and Fli1, we interrogated expression of the mutually antagonistic transcription
factors Eklf/Klf1 and Fli1 in Rgs18 manipulated cells. Klf1 and Fli1 are essential for the generation
of the erythroid and megakaryocytic lineages respectively [99-101], while also actively suppressing
alternative lineage fates downstream of MEPs [102]. Likewise, the relative abundance of these factors
determines the lineage choices adopted by the progeny of these bipotent progenitors. Yet how one
factor gains dominance over the other and vice versa during lineage specification remains unclear.
Therefore, to determine if these factors act downstream of Rgs18 we assessed their levels in cells
manipulated for the latter. In both lineages, Rgs18 levels correlated directly with Fli1, and inversely
with Klf1, message levels indicating that Rgs18 arbitrates alternative fates by ultimately regulating
relative Klf1 and Fli1 stoichiometries (Figure 34 A-D).
Additionally to confirm Rgs18 action upstream of Fli1, Fli1 was ectopically expressed in fetal liver
cells depleted of Rgs18 and then induced to differentiate along the megakaryocyte lineage. Ectopic
expression of Fli1 “rescued” the megakaryocytic potential of these cells as evidenced by the recovery
of expression of megakaryocytic differentiation markers (Figure 35 A) and histochemical (Ache
positive cells) staining of the doubly manipulated cells (Figure 35 B) to control levels. This was
further confirmed by surface expression of the megakaryocytic markers CD9 and CD41 by FACS
analysis of Rgs18k/d+Fli1o/e doubly manipulated cells relative to controls (Figure 35 C).
In addition to validate the above mentioned results further, Rgs18-Fil1 manipulated cells were grown
in methylcellulose medium supplemented with megakaryocytic cytokines and the number of
megakaryocyte colonies per 105 cells determined (Figure 36 A-B). Presence of similar megakaryocyte
colony counts in Rgs18k/d+Fli1o/e group relative to control confirmed the role of Fli1 downstream of
Rgs18 in promoting megakaryocyte differentiation.
Overall, these results established new and important functional connections between Gfi1b, Rgs18,
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MAPK cascades and relative Klf1/Fli1 levels in charting distinct cell fates downstream of bipotential
progenitors.
3.3.2. Identifying proteins associated with Rgs18 in megakaryocytic cells.
Consistent with its identity as a GAP factor, Rgs18 is known to interact with Gαi and Gαq subunits
of G proteins and with scaffolding proteins like 14-3-3 and Spinophilin in platelets to mediate its
GAP activity [64]. However, these may represent only a small subset of Rgs18 interacting proteins.
Additionally Rgs18 partners in erythroid cells if distinct from those in megakaryocytes are entirely
unknown. Therefore, to understand the mechanism of Rgs18 action during erythro-megakaryocyte
development particularly its differential regulation of MAPK signaling in these lineages, it seems
essential to determine its full repertoire of interacting proteins in both lineages. Moreover, since
Rgs18 produces opposite effects in the erythroid and megakaryocytic lineages, it may well do so
by engaging with lineage specific factors in addition to common ones in these cells. Therefore, we
endeavored to identify additional Rgs18 interacting proteins by affinity purification followed by
mass spectrometric analysis initially in megakaryocytic cells while similar experiments have been
planned for erythroid cells. For this purpose the Rgs18 coding sequence was fused to a short
epitope tag known to undergo in vivo biotinylation by the bacterial biotin ligase (BirA). The Rgs18biotag expression vector was co-transfected with the BirA expression vector into L8057
(megakaryoblastic) and MEL (erythroid) cells to generate stable cell lines (Figure 37). L8057 cells
stably expressing Rgs18-biotag and BirA was used for the subsequent affinity purification of the
Rgs18 interactome.
Biotinylated Rgs18 along with its associated proteins were captured from whole cells extracts on
streptavidin agarose beads. The affinity purified protein complexes from L8057 expressing either
BirA alone (control) or BirA and Rgs18-biotag were resolved by SDS-PAGE and subjected to
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whole lane mass spectrometry. Figure 38 shows a selective list of peptides mostly unique to the
Rgs18-biotagged lane in megakaryocytic cells obtained from three mass spectrometry analysis.
Although preliminary, this screen has begun to reveal potentially interesting interaction partners
of Rgs18 that on further analysis should produce major insights into the mechanism of action of
this crucial signaling molecule.
Preliminary analysis of Rgs18 interacting proteins in megakaryocytes has identified G proteins
(Gαi2, Gβ like1, cluster of G(i)G(s)G(t), Gαs), proteins of the cAMP pathway (PKA, CAP1,
Adenylase cyclase type 10), proteins of the Ras-MAPK signaling cascade (Rap1, Ras GTPase
activating like protein, Ras GAP binding protein, MAPK1-ERK2), scaffolding protein like 14-33, integrins and cytoskeletal proteins like Talin1 and Kindlin3 of which the latter are also Gfi1b
targets (D. Singh et.al, manuscript in preparation). A cumulative list of selective peptides obtained
from the three mass spectrometric analyses is shown in Figure 38. The Rgs18 interacting proteins
are categorized based on their ontology and affiliation. Among these proteins 86 peptides of Gαi2
was obtained in the experimental Rgs18-biotagged lane in the third experiment compared to the
control lane which showed 2 peptides. This confirms previous reports that noted interaction of
Rgs18 with Gαi in megakaryocytes and strongly indicates that Gαi2 is one of the most potent Rgs2
interactors [66, 69, 103]. If Rgs18 accelerates GTP hydrolysis by Gαi2 then it should activate the
cAMP pathway which operates downstream of and is inhibited by Gαi proteins (Figure 41).
Interestingly, apart from interacting with Gαi2, Rgs18 also interacts directly and/or intimately with
other proteins of the cAMP pathway (PKA, Adenylase cyclase associated protein 1 and Adenylase
cyclase type 10). Rgs18 was also found to associate with multiple Ras family proteins and RASMAPK pathway proteins in this analysis. The cAMP pathway and PKA inhibits ERK-MAPK
phosphorylation [96]. Although the consequence of the interaction of Rgs18 with the other
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components of the cAMP pathway is not clear from our present results, Rgs18 likely inhibits ERK
signaling by activating the cAMP pathway either via Gαi inhibition or by direct engagement.
Although there are conflicting reports in the literature regarding the role of ERK signaling in the
proliferation versus differentiation of megakaryocyte progenitors[71, 98], our results would
suggest that suppression of ERK signaling by Rgs18 is responsible at least partly for increased
differentiation.
On the other hand as members of the Ras pathway also came up as Rgs18 interacting proteins in
this analysis, it can be interpreted that Rgs18 by interacting with RasGAPs may also directly
accelerate GTP hydrolysis by Ras proteins and thus inhibits the Ras-Rac-MEK-ERKMAPK
pathway in ways not previously appreciated and which could further enhance megakaryocyte
differentiation (Figure 41).

Integrins (integrin β2, integrin β1, integrinα -4, integrin L), Rap1 and the cytoskeletal proteins
Kindlin3 and Talin1 obtained in these screens are also known to activate platelet aggregation [104].
Previous reports have shown the direct interaction of Kindlin3 and Talin1 with αIIb/β3 integrin
[104, 105] facilitates terminal differentiation of mature megakaryocytes into nascent proplatelets
[106]. Rap1 also a member of the Ras subfamily is stimulated by GPCRs, cytokine receptors and
cell adhesion molecules. Rap1 activation induces its association with Talin1 which in turn leads to
integrin-Talin1 interactions [104], while Kindlin3 and talin1 cooperatively bind with and activate
integrins [107]. It is not clear how interaction of Rgs18 with these cytoskeletal proteins leads to
megakaryocytic differentiation, given the complexity of the interactions involving Rgs18 with
these and other proteins. Disrupting specific associations may help illustrate their individual or
collective contributions.
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Chapter 4: Discussion and Future Directions.
During the process of lineage specification from multipotent progenitor cells in hematopoiesis, a
bipotent progenitor cell usually undergoes a discrete cell fate decision by committing to one of
two fates of predefined cell lineages [13]. This lineage commitment is achieved by expression of
cell type specific transcriptomes that are either stochastic or determined by extracellular signals in
the form of hematopoietic cytokines. Previous studies have shown differential expression of
various transcription factors (GATA1, GATA2, Klf1 and Fli1) during specification of the
erythroid and megakaryocytic cell fates from a bipotent MEP cell in determining outcomes [34].
In this report we have identified a signaling molecule Rgs18, a prominent transcriptional target of
Gfi1b in instigating lineage specification downstream of MEPs along with its repressor.
4.1. Regulation of Rgs factors during differentiation of hematopoietic cells.
We identified Rgs18 as a prominent target of Gfi1b and its co-repressor LSD1 in erythromegakaryocytic cells. Rgs18 was found to be stringently repressed by Gfi1b and LSD1 in erythroid
cells while being robustly expressed in megakaryocytes due to reduced expression of these repressors.
These expression patterns then support stimulation of megakaryocytic, and suppression of erythroid,
differentiation respectively, by Rgs18. These results thus introduce Rgs18 as a new arbitrator of
erythro-megakaryocytic differentiation and provide a novel perspective on the regulation of these
lineages by Gfi1b and its target, Rgs18. Given that Gfi1b performs similar functions in fetal liver and
bone marrow hematopoiesis [40, 46], this paradigm may hold true for the divergence of bone marrow
MEPs as well. Whether Rgs18 arbitrates similar lineage divergence at other cellular branch points
and/or is prototypic of the function of other Rgs proteins widely expressed in multiple tissues,
hematopoietic and otherwise, are fascinating and germane questions that need to be investigated in
light of the above observations.
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Germline and conditional gfi1b deletions have demonstrated the essential requirement of this gene for
the normal production and development of MEPs and their erythroid and megakaryocytic progeny
[40, 46]. Hence absence of gfi1b leads to an ablation of both lineages and produces either embryonic
lethality upon germline deletion [40] or adult mortality upon conditional deletion of this gene in the
bone marrow [46]. What our current results highlight is the differential expression of, and requirement
for, this factor subsequent to the initial specification of these lineages. Robust and sustained expression
of Gfi1b in the progeny of MEPs is required for erythroid identity and differentiation, in part by
suppressing megakaryocytic gene expression including that of Rgs18 until the erythroblast stage. Any
decline in Gfi1b levels subsequent to this stage may then be required for terminal erythroid maturation
[42]. Conversely, downregulation of Gfi1b in maturing megakaryoblasts and subsequent stages is
necessary for de-repression of genes like Rgs18 that promote differentiation of this lineage. Other
reports have shown Rgs18 to be repressed in erythroid cells by GATA1 [108], although it is not clear
if this repression pattern is maintained in megakaryocytes as GATA1 expression is also downregulated
during differentiation [109]. Therefore the rgs18 promoter could potentially be co-operatively
repressed by Gfi1b and GATA1 in erythroid cells while being derepressed by the downregulation of
both factors in megakaryocytes.
In addition to Rgs18, several other Rgs factors are derepressed to varying degrees upon loss of gfi1b
(Figure 39). Of these Rgs14 and Rgs2 are also chromatin targets of Gfi1b and its cofactors (LSD1
and Rcor1) in erythroid cells (S. Saleque et.al. unpublished). Therefore other Rgs factors may cooperate with Rgs18 in promoting one (megakaryocytic) versus the other (erythroid) lineage to mediate
multi-factorial regulation of this lineage divergence.
Rgs18 is also prominently expressed in platelets [110] where it potently inhibits processes like platelet
activation and aggregation by inhibiting G protein signaling [68, 111]. Therefore, this GAP factor
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performs distinct and even opposite functions in megakaryopoiesis versus thrombopoiesis.
4.2. Antagonistic regulation of erythro-megakaryocytic differentiation by Gfi1b and Rgs18.
The molecular events initiating the divergence of erythroid (red blood cell) and megakaryocytic
(platelet precursor) lineages from a bipotent progenitor are not entirely clear. As mentioned earlier
several transcription factors along with Gfi1b, signaling molecules and lineage specific genes have
been identified as essential for erythro-megakaryocytic lineage development where their expression
drives progenitor cells towards either of the two lineages [28]. Despite the recognition of these
molecules as key regulators of these lineage specifications, their mechanism of action and the signaling
cascades regulated by them are still not entirely clear. Here we have identified a reciprocal relationship
between the transcriptional repressor Gfi1b and its gene target Rgs18 during specification of the
erythroid and megakaryocyte lineages. In our current model (Figure 40) we propose that a gradual
decrease in Gfi1b levels produces an inverse increase in Rgs18 levels to promote the differentiation
of MEPs along the megakaryocytic lineage. Rgs18 then stimulates differentiation by negatively
regulating both the p38 and ERK branches of the MAPK pathway and expression of Klf1 while
positively regulating the expression of Fli1. In contrast, robust and increasing Gfi1b expression during
erythroid differentiation results in suppression of Rgs18 expression during the differentiation of these
cells. Reduced Rgs18 expression in turn promotes activation of the p38-MAPK pathway and down
regulation of ERK-MAPK signaling to boost Klf1 over Fli1 expression and stimulate erythroid
differentiation.
4.3. Role of signaling pathways and Rgs18 interactors in facilitating erythromegakaryocytic lineage specification.
Several studies have demonstrated the role of p38MAPK and ERK signaling in the regulation of
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hematopoietic stem and progenitor cell expansion and differentiation [71, 98]. Yet their relationship
with upstream or downstream transcription factors and the processes regulated by them continue to
remain nebulous. The observations reported here now establish coherent connections between the
erythro-megakaryocytic transcription factor Gfi1b and MAPK pathways via G protein signaling
mechanisms. They further extend the signaling chain to reveal regulation of Klf1 and Fli1 by these
pathways.
Previously, manipulation of Rgs16 but not Rgs18, had been found to impact MAPK signaling in
megakaryocytes. According to that study, both Rgs16 and Rgs18 mRNAs were upregulated during
megakaryocyte differentiation in cord blood cells. But over-expression of Rgs16 mRNA in M07e
(human megakaryoblastic myeloid leukemia) cell line inhibited MAPK (mitogen activated protein
kinase) and AKT (protein kinase B) expression as shown by reduced phosphorylation of these proteins
in Western blots but Rgs18 over-expression had so such effect on these proteins [97] . Since our results
now clearly illustrate the effect of Rgs18 manipulation on p38 and ERK signaling in both erythroid
and megakaryocytic cells, this apparent discrepancy between the earlier results and ours may be a
consequence of the different cell types (human MO7e versus murine L8057 and MEL) or assays
employed in each study. Moreover our subsequent mass spectrometric data reveal that inhibition of
MAPK pathways which have been implicated in proliferation [71, 98] by Rgs18 are likely due to a
combination of inhibition of Gi and Ras signaling by this factor (Figure 41).
Based on the Rgs18 interaction proteins obtained from the mass-spectrometry results a possible link
between Rgs18-MAPK-Klf1 has been outlined. p38-MAPK and Klf1 are both known to be required
for and to stimulate erythropoietic differentiation [72, 100]. So even though we do not known if Klf1
is directly regulated by p38-MAPK pathway we found its expression to correlate directly with p38
phosphorylation levels. Even though a direct connection cannot be determined but a causal link
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between p38 phosphorylation and Klf1 may be tested by inhibiting one or the other.
4.4. Relevance of Rgs18 functions to hematopoietic diseases and their control.
Various lines of evidence demonstrate that Rgs18 stimulates megakaryocytic differentiation [63, 67]
while limiting platelet aggregation and activation by turning off G q signaling [64, 68, 111]. We now
demonstrate the key role played by this factor in ensuring erythro-megakaryocytic homeostasis by
actively suppressing the erythroid and promoting megakaryocyte differentiation. These insights could
potentially be utilized to rectify imbalances between erythroid and megakaryocytic cell generation that
lead to hematopoietic abnormalities. Accordingly, a deficit in erythropoiesis could conceivably be
compensated by inhibiting Rgs18 (or other Rgs proteins that work similarly and co-operatively in
these cells) and/or by indirectly stimulating G protein signaling. Conversely, thrombocytopenia
resulting from G protein signaling problems or other deficits could be offset by stimulating Rgs18
expression or activity, and/or by inhibiting specific G proteins.
In conclusion, our study presents Rgs18 as a key regulator of erythro-megakaryocyte lineages
specification, downstream of the transcription factor Gfi1b. These effects are mediated by differential
MAPK signaling and alterations in Klf1:Fli1 levels. As mentioned above, these molecular insights
into the divergence of the erythroid and megakaryocytic lineages from MEPs could also provide
rational platforms for developing strategies for stimulating one or the other lineage when depleted by
diseases or environmental assaults.
4.5. Summary.
In this report, the dual role of a signaling molecule Rgs18 was shown in specification of erythroid and
megakaryocyte lineages in hematopoiesis. Rgs18, a GTPase activating protein was identified as one
of the gene targets of the transcriptional repressor Gfi1b through ChIP on Chip screen in erythroid
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cells. Previous studies have already established the essential role of the site specific transcriptional
repressor Gfi1b in erythro-megakaryopoiesis but its mechanism of action and functional role in these
processes remains elusive.
Now, we have demonstrated that Rgs18 along with its transcriptional repressor Gfi1b arbitrate
specification of erythroid and megakaryocyte lineages in human and mouse cells. Gfi1b stringently
represses Rgs18 expression in erythroid cells, while during megakaryocytic differentiation, declining
Gfi1b levels facilitate robust induction of the latter. Concordantly, alterations in Rgs18 expression
produce disparate outcomes by augmenting megakaryocytic and potently suppressing erythroid
differentiation and vice versa. These phenotypes reflect differential impact of Rgs18 on p38 and ERK
signaling in the two lineages, which in turn alter the balance between the mutually antagonistic
transcription factors, Fli1 and Klf1. Overall these results identify Rgs18 as a new and critical effector
of Gfi1b that regulates downstream signaling and gene expression programs to orchestrate erythromegakaryocytic lineage choices. Since Rgs18 was identified along with two other members (Rgs2,
Rgs14) of the Rgs family in ChIP on Chip screen, the dual role of Rgs18 in reciprocally regulating
divergent lineages presented here could exemplify generic mechanisms characteristic of these and
other family members in specifying alternative lineages in different contexts.
4.6. Future directions.
4.6.1. Analysis and prediction of rgs18 mutant physiology.
To understand the role of Rgs18 in mammalian physiology, we have generated rgs18 mutant mice.
Two recent reports of functional Rgs domain deleted rgs18 mutant mice have revealed either a
gain of function phenotype in platelets with enhanced occlusion time at sites of vascular injury and
enhanced bleeding time or defective megakaryopoiesis followed by mild thrombocytopenia in
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mice [67, 68]. However, these recent studies with Rgs18 mutants did not report any differences in
erythropoiesis between the controls and mutants. Since our ex-vivo experiments have demonstrated
enhanced differentiation of erythroid cells upon Rgs18 inhibition in FLCs it is likely that these
mice may have mild to moderate erythrocytosis (increased number of RBC) that may have been
undetected or overlooked by these researchers given that the regulation of erythropoiesis by Rgs18
was previously unknown and/or may not noticeably impair the health of these mice over and above
that due to the defects in megakaryopoiesis and clotting. Moreover these studies have reported
phenotypes resulting from mutants with partially deleted RGS domain of Rgs18. Therefore it is
not clear if these knock outs represent null or hypomorphic mutations of rgs18. Since the 235
amino acid codons of rgs18 are distributed over 5 exons with the RGS domain (comprised of 127
amino acids) spanning exons 3-5, deletion of the RGS domain from exon 4 onward does not
completely delete the gene and may not completely abrogate its function. Therefore, we have
generated rgs18 mutants with frame-shift mutations in the first exon of the rgs18 gene that should
result in premature termination of the open reading frame with severely truncated proteins or none
at all and so result in a true null mutations. Following their initial characterization by genotyping,
three independent rgs18 mutations were identified and gene edited heterozygous mice were
derived from them. These mice are currently being mated with wild type mice to expand the colony
and the resulting heterozygotes will be mated to produce homozygotes for phenotypic analysis as
outlined below:
a) Firstly E12.5 day embryos obtained from the timed mating of rgs18 +/- mice will be genotyped.
The expected Mendelian ratio (1:2:1) of wild type, heterozygous and mutant embryos would
be verified by genotyping and morphology of the mutant embryos would also be examined.
Peripheral blood of rgs18+/+, rgs18+/- and rgs18-/- embryos will be compared at E12.5-14.5
50

gestation stages by staining the yolk sac blood cells with May-Grunwald-Giemsa stain (MGG).
FACS analysis of the WT versus mutant FLCs doubly stained with antibodies against Ter119
(mature erythroid marker) and c-kit (marker for immature hematopoietic cells) will be
performed. Since we know from the ex vivo studies that Rgs18 is a negative regulator of
erythropoiesis, we are expect that absence of Rgs18 to result in a higher ratio of mature
erythroid cells compared to the wild type. Thus, the MGG stain should show more mature adult
enucleated red blood cells in the rgs18 -/- blood samples and higher percentage of c-kit -Ter119+
cells in FACs analysis compared to the wild type cells.
b) Since Rgs18 positively regulates megakaryopoiesis and negatively erythropoiesis, we expect
absence of Rgs18 to result in defects in production, maturation and total counts of these cells.
Thus to analyze the effect of Rgs18 deletion in megakaryopoiesis, the FLCs from E12.5 rgs18/- and wild-type embryos will be cultured ex vivo with the megakaryocytic cytokines. The
deficit in megakaryopoiesis, if any, will be examined by acetylcholine esterase (Ache) assays,
qPCR analysis of megakaryocyte markers and flow cytometric analysis of CD9 and CD41
expression of rgs18-/- versus rgs18+/+ cells. Since we predict at least a reduction in
megakaryocytic differentiation in rgs18-/- cells, therefore we expect to obtain fewer of Ache
(+) ve cells, lower expression of megakaryocyte markers and lower numbers of CD9+CD41+
cells in the mutants relative to wild type or heterozygous controls.
c) In parallel, the expression pattern of different Rgs proteins especially the ones known to be
highly expressed in megakaryocytes along with Rgs18 (Rgs16, Rgs10) as well as the other
Gfi1b targets from the Rgs family (Rgs2 and Rgs14) will be quantified in rgs18-/- fresh FLCs
and those induced towards erythroid and megakaryocytic differentiation. This will be
performed to determine if their expression levels were affected due to rgs18 deletion and may
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indicate compensation at the level of expression or function among Rgs family members, if
any. Although, prior rgs18 knock outs [68] have reported no detectable change in Rgs16 and
Rgs10 expression, we may see an increase in the expression of these proteins as well as Rgs2
and Rgs14 in our null animals.
d) Whether or not we observe over-expression of other Rgs proteins rgs18-/- FLCs they will be
knocked them systematically and combinatorically in the rgs18-/- cells to determine functional
synergy between them.
4.6.2. Determine Rgs18 interacting proteins in erythroid cells.
As mentioned in the result section, preliminary data from the mass spectrometric analysis have
identified different interactors of Rgs18 in megakaryocytes. Since manipulation of Rgs18 shows
distinct and opposite phenotypes (positive regulation of megakaryopoiesis while negative effect on
erythropoiesis) in the two lineages, there may be a different interacting partners of Rgs18 in the two
lineages. Thus in the future Rgs18 interactors in the erythroid lineage will be similarly identified by
affinity chromatography and mass spectrometry. The data obtained from these experiment will very
likely divulge the mechanism(s) responsible for the differential even opposite effects exerted by Rgs18
on ERK signaling in erythroid versus megakaryocytic cells which may be a major determinant in
specifying divergent outcomes in the two lineages. Thus the knowledge of Rgs18 interactors will
provide unprecedented insights into the regulation of signal transduction, particularly MAPK
pathways, by Gfi1b via its transcriptional target Rgs18.
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Figures

Figure 1: Ontogeny of mouse hematopoiesis.
Mesoderm forms at gastrulation (E6.5), then blood islands develop within the yolk sac
(E7.5), followed by emergence of HSCs in the AGM region (E10.5) and in placenta (E10.5-

11). Finally fetal liver hematopoiesis occurs between E11.5-E14.5 and shifts to the bone
marrow at E18.5 and then continues throughout adult life.

(Ref: Baron et al. Blood cells, Blood cell, Molecule, and Diseases, 2013. 51 (4):p.213-219.)
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Figure 2: Classical model of adult hematopoiesis.
ST-HSCs produce multipotent progenitors such as the common myeloid progenitor,

which further diverge to cells with megakaryocyte erythroid potential (MEPs) and
granulocyte macrophage (GMP) potentials. The MEPs subsequently diverge to produce

to erythroid and megakaryocyte cells. The yellow highlight shows the divergence of
erythroid and megakaryocyte lineage from MEPs.
(Ref: Wang et al Nature reviews 2011)
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Figure 3: Transcription factors regulating commitment of HSCs to MEPs.
Dual expression of GATA1 and PU.1 causes HSCs to differentiate into common

myeloid progenitors. Subsequently dominance of GATA1 expression over PU.1
directs CMPs to the EMP/ MEP fate.

(Ref: Zhu et al. Oncogene, 2002. (21): p. 3295-3313.)
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Figure 4: Mutual antagonism between EKLF/Klf1 and Fli1 during erythromegakaryopoiesis.

Erythro-megakaryocyte cell fate determining factors Klf1 and Fli1 establish cell fate by
cross inhibiting each other’s promoters.

(Ref: Modified from Dore et. al. Blood 2011.118 (2):p. 231-9.)

Figure 5: Regulation of erythro-megakaryocytic cytokine receptors by EKLF/ Klf1
and Fli1.

Mutually antagonistic transcription factors Klf1 and Fli1 not only cross-inhibit each but
also regulate erythropoietin and thrombopoietin receptor expression.

(Ref: Shah et al. Journal of cell science, 2015. 128 (16): p30009-17.)
56

Figure 6: Regulators of erythro-megakaryocyte development.
The development of mature erythroid and megakaryocyte cells from their progenitors is
controlled by transcription factors and signaling proteins. Those aberrantly expressed in

erythroleukemias are highlighted in red. Grey boxes indicate factors necessary for initial
specification of erythro-megakaryopoiesis. The yellow box highlights the transcription

factor Gfi1b and shows its role at different stages of erythro-megakaryocyte
development.

(Ref: Vincenta et al. Critical review of ontology/ Hematology 2012.82:p.1-17)
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Figure 7: Schematic representation of Gfi1 and Gfi1b.
Their respective SNAG repression domain and DNA binding Zinc finger domain are
highlighted in red and blue respectively.

(Ref: Saleque et al. Molecular cell, 2007. 27 (4): p. 562.572)

Figure 8: Gfi1b is required for definitive erythropoiesis.
Control and gfi1b -/- embryos and blood at embryonic day 10.5, 12.5 and 14.5, respectively.
gfi1b -/- embryos show aberrant primitive erythroid cell morphology and delayed cell
maturation and a complete lack of enucleated definitive erythroid cells.
(Ref: Saleque et al. Genes & development, 2002. 16 (3): p. 301-306.)
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Figure 9: gfi1b -/- fetal livers shows arrested megakaryopoiesis.
gfi1b -/- fetal liver cells when induced to differentiate in culture exhibit a complete

differentiation arrest as seen from visualization of cell morphology (e) and absence
of acetylcholine esterase staining (f).

(Ref: Saleque et al. Genes & development, 2002. 16 (3): p. 301-306.)
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Figure 10: Mechanism of transcriptional repression by Gfi1b.
Gfi1b recruits its chromatin modifiers to chromatin targets to alter histone marks.
Recruitment of LSD1 and HDAC to the DNA results in demethylation of K4 and
deacetylation of K9 residues respectively.

Recruitment of G9A by Gfi1b facilitates

methylation of H3-K9, resulting in stable, long-term silencing of the locus.
(Ref: Meer et al. Leukemia, 2010. 24 (11): p. 1834-1843.)
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Figure 11: Diagrammatic representation of Gfi1b, LSD1, and CoREST targets.
CHIP on Chip screen data of Gfi1b and its cofactors (LSD1 and CoREST). Each factor

has its independent target genes indicated in brackets. The targets that are either unique

to each other or common to one or more of them are indicated in the corresponding
region of the diagram. All three shares 653 common target genes between each other.
(Ref: Saleque et al. Molecular cell, 2007. 27 (4): p. 562.572.)
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Figure 12: Domain architecture of three Rgs family members that are gene targets of
Gfi1b.

Rgs2 and Rgs18 belongs to the R4 subfamily of Rgs proteins which contain only one RGS
domain while Rgs14 belongs to the R12 subfamily that has 1RGS domain, 2 Raf like Rasbinding domains, 1 GoLocco domain.

(Ref: Modified from Richard et al. Nature Reviews Drug discovery 2002 (1) p: 187)
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Figure 13: Regulation of G protein signaling by Rgs proteins.
Rgs proteins are GTPase activating proteins (GAPs) that accelerate GTP hydrolysis by Gα
subunits of heteromeric G proteins and downregulate GPCR and the G protein mediated
signaling.

(Ref: http://koslofflab.haifa.ac.il/index.htm)
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Figure 14: Role of the MAPK pathway in hematopoiesis.

Initial activation of p38 and ERK pathways are essential for development of megakaryocyte

erythroid progenitors from CMP. p38 is essential for the final maturation of erythroid lineage.
Positive effect on lineage development is indicated in green whereas the inhibitory effects are
depicted in red.

(Ref: Gest et al. Journal of leukocytes biology, 2009. 86 (2): p.237-50.)
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Figure15: Schematic representation of Rgs18 guide RNA design strategy.
Section of Rgs18 genomic DNA with exon1 highlighted in yellow. Numbers and under lines

represent the sequences corresponding to the four gRNAs. Sequences of primers used to
amplify Rgs18 exon1 are highlighted in blue. The initiator ATG is highlighted in orange.
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Figure 16: Rgs18 mutant primers sequence positions.
Sequences of primers specific for amplifying lesions present in founders, #34 and #38 are
underlined and the alterations in the genomic sequence highlighted in pink (deletion) and
yellow (insertion).
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Figure 17: Annotated Rgs18 promoter sequence.
Rgs18 promoter sequence obtained from ChIP-on-chip sequence experiments with Gfi1b/LSD1/Rcor1

in MEL cells. The transcriptional start site is indicated by the underlined bold maroon letter G. The
initiator ATG codon is indicated in bold green letters. The consensus (AAATCA) and quasi-consensus

(AAATCT) Gfi1/1b binding elements are indicated in bold blue letters and the sequences of the
primers used for ChIP qPCR amplification used in Figure 19 are underlined.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 18: Expression pattern of Rgs18, Gfi1b, and LSD1 proteins in erythromegakaryocytic cells.

Western blot documenting Gfi1b, LSD1, Rgs18 and b-actin (as loading control)
protein levels in uninduced (-TPA and -DMSO) and induced (+TPA and +DMSO)
L8057 (Mk line) and MEL (Ery line) cells. 60µg protein was loaded in each lane.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure19: ChIP experiment showing enrichment of Gfi1b/LSD1 on rgs18
promoter segments.

Enrichment of Gfi1b and its cofactor LSD1 on upstream (u) and downstream (d)
rgs18 promoter segments (rgs18p) in uninduced and induced (A) megakaryocytic
(meg) and (B) erythroid (ery) cell lines relative to a mock (IgH switch Sm) locus.

Mean and sd (±) from three independent ChIP experiments are shown. P values

were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were
calculated using Anova and student t test (Courtesy: G. Upadhyay).

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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A

Figure 20: Rgs18 expression pattern in LSD1 inhibited uninduced MEL and L8057 cells.
A. LSD1 mRNA levels in uninduced L8057 (meg) and MEL (ery) cell lines knocked down for
LSD1 (sh-LSD1) versus controls (Scr-ctrl). B. Relative Rgs18 mRNA levels in control (Scr-Ctrl;
scrambled) and LSD1 inhibited (sh-LSD1) erythroid (ery; MEL) and megakaryoblastic (meg;

L8057) cells. Mean and sd (±) from three independent experiments are shown. P values were
<0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were calculated using Anova
and student t test.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519)

70

Figure 21: Composition of E12.5 fetal liver cells.
Expression of CD71 and Ter119 surface markers in FACs sorted E12.5 fetal liver cells. 84.5%
cells exhibited robust ter119 (mature erythroid marker) expression.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519)

Figure 22: Expression pattern of Gfi1b and Rgs18 in Gfi1b mutant and wild type FL cells.
Gfi1b and Rgs18 mRNA levels in gfi1b+/+, gfi1b+/- and gfi1b-/- e12.5 total fetal liver (FL
cells).

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 23: Time course of Rgs18 expression pattern in gfi1b+/+ and gfi1b-/- fetal liver
cells.

A.Time course (from day 0-5) of GPIIb (glycoprotein IIb/CD41), Gfi1b and Rgs18 message

levels in wild type e12.5 fetal liver cells differentiated along the megakaryocyte lineage

relative to day 0 (d0), following normalization for HPRT. B. Rgs18 mRNA levels in WT
(Gfi1b+/+) and mutant (Gfi1b-/-) fetal liver cells cultured along the megakaryocytic lineage

for the indicated periods. Mean and sd (±) from three independent experiments are shown. P
values were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were
calculated using Anova and student T test.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 24: Rgs18 promotes differentiation of the megakaryocytic cell line, L8057.
A. Western blot of Rgs18 protein levels upon inhibition and over-expression in the
megakaryocytic line L8057. 50µg protein was loaded in each lane B. qPCR analysis of Rgs18
mRNA level and differentiation markers upon Rgs18 inhibition. C. qPCR analysis of Rgs18
mRNA level and differentiation markers upon Rgs18 over-expression. D. Acetylcholine esterase
staining of Rgs18 manipulated cells. Mean ± sd of acetylcholine positive cells as a % of the total

population from three independent experiments is indicated in parentheses. E. Megakaryocytic
marker expression in cells expressing both Rgs18 shRNAs and cDNA (±Rgs18) versus controls.
Mean and sd (±) from three independent experiments are shown. P values were <0.0001 (****),

<0.001 (***), <0.01(**) and <0.05 (*) respectively were calculated using Anova and student T
test.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 25a: Augmentation of megakaryocytic differentiation by Rgs18.
A.qPCR analysis of Rgs18 mRNA levels and differentiation markers GPIIb, PF4 (platelet
factor 4) and vWF (vonWillebrand factor) upon shRNA mediated Rgs18 inhibition (sh-Rgs18)
relative to scrambled shRNA controls (Scr-Ctrl) in e12.5 fetal liver cells differentiated into

megakaryocytes. B. qPCR analysis of analogous markers upon Rgs18 cDNA/protein overexpression (Rgs18 o/e) relative to vector control (pCDH-Ctrl) in the same cells. . Mean and sd

(±) from three independent experiments are shown. P values were <0.0001 (****), <0.001
(***), <0.01(**) and <0.05 (*) respectively were calculated using Anova and student T test.

C. Western blot of total Rgs18 protein levels following inhibition and over-expression as
indicated, in primary (fetal liver derived) megakaryocytes relative to b-actin. 35µg of protein
was loaded in each lane.
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Figure 25b: Augmentation of megakaryocytic differentiation by Rgs18.
D. Acetylcholine esterase staining of Rgs18 manipulated cells as indicated. Mean ± standard

deviation of acetylcholine positive cells as a percent of the total population from three
independent experiments is indicated in parentheses. E. FACs analysis of CD9 and CD41
expression in fetal liver cells cultured into megakaryocytes following the indicated
manipulations into as indicated. One of three representative experiments is shown.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 26: Rgs18 suppresses differentiation of the erythroid cell line, MEL.
A.Western blot of Rgs18 protein levels upon inhibition in MEL (erythroid) cells. 50 g protein
was loaded in each lane. B. qPCR analysis of Rgs18 message and differentiation markers upon

Rgs18 inhibition. C. Benzidine staining of Rgs18 manipulated cells. Mean ± standard deviation
of benzidine positive cells as a % of the total population from three independent experiments is
indicated in parentheses. D. Erythroid marker expression in cells expressing both Rgs18 shRNAs
and cDNA (±Rgs18) versus controls. Mean and sd (±) from three independent experiments are

shown. P values were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were
calculated using Anova and student T test.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 27: Suppression of erythroid differentiation by Rgs18.
A. qPCR analysis of Rgs18 message levels and differentiation markers EB3 (erythrocyte band
3), GypA (glycophorinA/ter119) and Globin (b major globin) upon shRNA mediated Rgs18
inhibition (sh-Rgs18) relative to controls (Scr-Ctrl)) in e12.5 fetal liver cells differentiated

along the erythroid lineage B. qPCR analysis of the same erythroid markers and cells upon

Rgs18 cDNA/protein over-expression (Rgs18 o/e) relative to vector control (pCDH-Ctrl). P
values were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively. C. Benzidine

staining of Rgs18 manipulated erythroid cells as indicated. Mean ± standard deviation of
acetylcholine positive cells as a percent of the total population from three independent

experiments is indicated in parentheses. D. FACS analysis of the surface markers ter119 and

c-kit in control and Rgs18 manipulated fetal liver cells cultured into erythroid cells as
indicated. Averages and standard deviations from 3 independent experiments are shown in AC. Results from one of three representative experiments is shown in D.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 28. Reciprocal regulation of erythro-megakaryocytic lineage specification by
Rgs18.

A. Isolation of hematopoietic (lin-c-kit+) progenitors from e12.5 fetal liver cells for

transduction with Rgs18 cDNAs (Rgs18o/e) and shRNAs (sh-Rgs18) in B. B. Expression

of erythroid and megakaryocytic surface markers ter119 and CD41 respectively, in lin-ckit+ progenitors co-cultured with a mixture of erythroid and megakaryocytic cytokines

following the indicated manipulations. Results from one of three representative experiments
is shown in B (courtesy G. Upadhyay).

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 29. Expression and manipulation of Rgs18 in K562 cell line.
Expression of Rgs18 (A) and other messages as indicated in the human hematopoietic cell line K562

transduced with Rgs18 cDNA and differentiated along the erythroid (+Na but) (B) or megakaryocytic
(+TPA) (C) lineages. D. Total Rgs18 and b-actin protein levels in uninduced K562 cells (Un; top two

panels) and upon differentiation into erythroid (+Na-but; middle two panels) and megakaryocytic

cells (+TPA; bottom two panels), respectively. E. Histochemical staining of K562 cells differentiated
along the erythroid (top panels) or megakaryocytic (bottom panels) lineages following transduction
with empty vector (pEF4-Ctrl) or Rgs18 cDNA (Rgs18 o/e). Erythroid cells were stained for

benzidine (top panels), megakaryocytic cells were visualized by generic May-Grunwald Giemsa
staining (bottom panels). Mean and sd (±) from three independent experiments are shown. P values

were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were calculated using

Anova and student T test. Averages and standard deviations from 3 independent experiments are
shown in A-C. (Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 30. Identification of indels in rgs18 founders.
A. Identification of indels in select rgs18 founders by the T7 endonuclease assay.
B. Nucleotide and amino acid sequence of exon1 of rgs18. The sequence altered
in the founders is indicated in bold maroon letters.

Mouse Mutation
#12
#34-1
#34-2
#38
#78-1
#78-2

4bp
2bp
2bp
4bp
2bp
1bp

del
del
ins
ins
del
del

Peptide sequence
(predicted)
GAAACA[AGCA]TCGAG SRPKSERKKKGIDstop
CAAGCA[TC]GAGGC
SRGQNQSERKKEstop
CACTGG{C}TTTTC
MDMSLAFLLSIKYVstop
CAAGCA{AAAA}TCGAGG SKNRGQNQSERKKEstop
CAAGCA[AT]CGAGG
SRGONQSERKKEstop
CAAGCA[T]CGAGG
SSRPKSERKKKGIDstop
DNA sequence

Figure 31. Characterization of mutations in rgs18 founders.
Nucleotide sequence analysis of rgs18 founder DNA flanking the lesion along with the
predicted amino acid sequence. Deletions in DNA sequence are indicated in red and the
insertions in blue. Altered amino acid sequence is indicated in red.
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Figure 32: Differential regulation of MAPK pathways by Rgs18.
A-B. Effect of Rgs18 inhibition (A) and over-expression (o/e) (B) relative to controls, on
pERK1/2 levels in induced L8057 [megakaryocytic (Mk) line +TPA]. Top panel: pERK1/2:

middle panel: total ERK1/2; bottom panel: β-actin. C. Effect of Rgs18 inhibition on the
MAPK-ERK1/2 pathway in induced MEL cells [Erythroid (Ery) line +DMSO). D-E. Effect
of Rgs18 inhibition (D) and over-expression (E) on p38-MAPK protein and phosphorylation

levels in megakaryocytes. Top panel: phospho p38: middle panel: p38α; bottom panel: bactin. F. Effect of Rgs18 inhibition on the p38-MAPK pathway in erythroid cells. 50µg of
protein was loaded in panels A,D,E,F and 80µg loaded in B&C. One of 3 representative

experiments is shown. G. Table summarizing the effects of Rgs18 manipulation on ERK1/2
and p38 pathways versus differentiation of erythro-megakaryocyte cells. Arrows indicate
increase () or decrease () in activity and differentiation (Diff), respectively.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 33: MAPK phosphorylation kinetics in differentiating megakaryocytes.
A.Time course of ERK phosphorylation (top panel) versus total ERK protein (middle
panel) and b-actin (loading control; bottom panel) in L8057 cells induced to
differentiated for the indicated periods (hours). B. Time course of p38 phosphorylation

(top panel) versus p38α protein (middle panel) and b-actin (loading control; bottom
panel) in L8057 cells induced to differentiated for the indicated periods (hours).
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 34: Changes in expression pattern of transcriptional effectors of Rgs18.
A-D. Klf1 and Fli1 mRNA levels (normalized for HPRT) in control versus Rgs18 inhibited (sh-

Rgs18; A, B) or over-expressing (C and D), fetal liver derived erythroid (A and C) and

megakaryocytic (B and D) cells. Mean and sd (±) from three independent experiments are
shown. P values were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were
calculated using Anova and student T test.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 35: Rescue of megakaryocytic differentiation in Rgs18-inhibited primary fetal liver cells.
A.qPCR assay showing rescue of megakaryocytic differentiation in Rgs18-inhibited (sh-Rgs18)

primary megakaryocytic cells upon Fli-1 overexpression (sh-Rgs18+Fli1o/e) as assessed by marker

analysis and acetylcholine esterase staining. B.The mean and sd± of acetylcholine positive cells as a

percentage of total population from three independent experiments as indicated in parentheses. P
values were <0.0001 (****), <0.001 (***), <0.01(**) and <0.05 (*) respectively were calculated
using Anova and student T test. C. Megakaryocyte markers CD9 and CD41 expression in fetal liver
cells cultured for 5 days along the megakaryocytic lineage following indicated manipulation.
(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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A

Figure 36: Samples of megakaryocytic colonies upon differentiation of fetal liver
cells.

A. Megakaryocyte colony numbers obtained from fetal liver cells cultured for 5 days

in methyl cellulose supplemented with IL-3 and thrombopoietin following Rgs18
inhibition (sh-Rgs18) and Rgs18 inhibition and Fli1 over-expression (shRgs18; Fli1
o/e) relative to scrambled controls (control). B. Samples of 5 day old megakaryocytic

colonies from control (scrambled), Rgs18 inhibited (sh-Rgs18) and Rgs18 inhibited

and Fli1 over expressing (sh-Rgs18+Fli1o/e) fetal liver cells following in vitro culture
in methyl cellulose supplemented with IL-3 and thrombopoietin. Mean and sd (±) from

three independent experiments are shown. P values were <0.0001 (****), <0.001

(***), <0.01(**) and <0.05 (*) respectively were calculated using Anova and student
T test in A.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 37: Diagrammatic representation of the process of purification of biotinylated
protein and its interactors.

Rgs18 was inserted into a vector with biotin tag. Both Rgs18-biotag and BirA plasmid were

expressed in L8057 (megakaryoblastic) and MEL (erythroid) cells. The interacting proteins
were pulled along with the biotinylated protein using streptavidin-agarose beads.
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Expt1
Protein name
Rgs18

Cluster of Guanine nucelotide-binding
protein g(i) subunit alpha-2
Cluster of G uanine nucleotide-binding
protein G(I)/ G(S)/G(T) subunit beta-2
Guanine nucleotide binding protein
subunit beta-2-like 1
Guanine nucleotide binding protein G(s)
subunit alpha isoforms
cAMP dependent protein kinase typeII-2
(PKA)
Adenylase cyclase associated protein
1(CAP1)
Adenylase cyclase type10
clusterof 14-3-3 (episilon)
Ras related protein Rap1
Ras related GTP binding protein b
Ras related protein Rap2b
Ran GTPAse activating protein (Ran)
Ras related GTP binding protein d
Ras protein activator like3 Rasal3
Ras related protein Rab14
Dual specificity MAPK7
cluster of MAPK1 (ERK2)
integrin beta-2
integrin beta-1
integrin alpha- 4
integrin alpha-L
integrin linked prtoein kinase
Kindlin3
Talin1
Talin2
Cluster of GTP binding nuclear protein
Ran
Rho GTPase activating protein
Proliferation associated protein2
G coupled receptor 56
GTP binding protein SAR1a
p21 activated protein kinase
GTP binding protein Rheb
osteoclast stimulating factor

Expt2

Expt3

Accession No.
Kda (UniProtKB/Sw BirA R18 BirA R18 BirA R18
iss-Prot)
28

Q99PG4.1
B2RSH2.1,
P08752.5,
Q9DC51.3
P62874.3,P6288
0.3,P2938.7

40
37
35

P68040.3

122

Q6RH7.1

0

1

2

4

2

86

3

4

0

11

0

2

4

23

0

1

1

4

46

P12367.2

0

2

0

13

52

P40124.4

0

3

1

11

3

5

0

1

0

12

0

2

0
0
0
0
0
17
0

5
1
1
1
22
106
7

0
3

1
8

186
29
21
43
21
64
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115
24
59
41
85
88
116
128
51
76
270
254

Q8COT9.2
P62259.1
P62835.1
Q6NTA4
P61226.1
P46061.2
Q7TT45.2
Q8C2K5
Q91V41.3
Q8CE90.1
P63085.3
P11835.2
P09055.1
Q00651.1
P24063.2
O55222.2
Q8K1B8.1
P26039.2
Q71LX4.3

92

Q3UIA2.1
P50580.3
Q8K209.1
P36536.1
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Q921J2.1
Q62422.2

24
77
22
42
20
24

88

P62827.3

4

5

0

1

0

1

0
0

2
1

0

4

4
2

7
7

3

4

0

2

0

1

0
0

0
0

7
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2
6

0
5
1
0
0
1
0

2

0
0
0
0

1
32
3
1
1
6
1

11

1
4
1
1

Figure 38: Potential Rgs18 interacting proteins.
A selective list of the number of independent peptides obtained from three independent mass

spectrometric analysis of affinity purified Rgs18 and protein complexes relative to a BirA
(control) from the uninduced L8057 (megakaryoblastic) cells. The peptides are categorized
based on their ontology, affiliation and highlighted with different colors. The yellow color

represents G protein group, blue Ras-MAPK pathway proteins, cAMP pathway proteins are
represented in orange, peptides from integrins and cytoskeletal proteins are represented in green,

scaffolding protein is represented by light blue. The peptides from proteins that cannot be
categorized in any section are written in black. Rgs18 is highlighted in red.
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Figure 39: Expression profiling of Rgs proteins in gfi1b+/+ and gfi1b-/- cells.
Relative message levels of multiple Rgs proteins known to be expressed in hematopoietic

cells, in gfi1b+/+ versus gfi1b-/- cells from e12.5 total fetal livers representing
predominantly erythroid populations. Mean and sd (±) were calculated from three
independent experiments. P values were <0.0001 (****), <0.001 (***), <0.01(**), <0.05
(*) respectively calculated by using student t test and Anova.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 40: Proposed model of regulation of erythro-megakaryocytic differentiation.
Proposed trajectory of erythro-megakaryocytic lineage specification from progenitors
(MEPs) as mediated by Gfi1b and Rgs18. Reciprocal expression of Gfi1b and Rgs18 in

erythroid and megakaryocytic cells is indicated by colored trapezoids; green being

stimulatory and red inhibitory. Alterations in signaling pathways and downstream gene
expression following differential Gfi1b and Rgs18 expression, are indicated by vertical
arrows.

(Ref: Sengupta, A. et al. Journal of Cell Science 2015 pii: jcs.177519.)
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Figure 41: Possible link between G protein signaling, cAMP and MAPK pathways and
their regulation by Rgs18 during megakaryocyte differentiation.

Rgs18 regulates the cAMP and Ras-MAPK pathways by possibly interacting with Gαi, CAP1,
PKA, RasGAP binding proteins and Ras-GTPase activating proteins that are essential for
modulation of AC-cAMP-PKA and Ras-MAPK pathways.
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